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Abstract.
The malarial parasite utilises amino acids drawn from the host 
haemoglobin for it's intraerythrocytic development. The 
endopeptidases described to date will only produce peptides from host 
haemoglobin. In order to obtain free aminoacids for incorporation in 
malarial proteins the malarial parasite requires exopeptidases (i.e. 
aminopeptidases and carboxypeptidases).
Aminopeptidase activity was described in human malarial 
parasites Plasmodium falciparum rodent malarial parasites 
Plasmodium chabaudi chabaudi and Plasmodium berghei. These 
enzymes were shown to be inhibited by the aminopeptidase inhibitor 
bestatin. In light of these findings, the antimalarial effects of bestatin 
were investigated both in vitro and in vivo. Bestatin inhibited the in 
vitro growth of P. c. chabaudi, of chloroquine sensitive P. falciparum 
clone FCH5.C2 and chloroquine resistant P. falciparum clone 
K 1/Thailand. P. chabaudi infection is naturally lethal to male mice 
whereas female mice develop protective immunity against a similar 
infection. In vivo investigation of the effects of bestatin showed that 
this aminopeptidase inhibitor could induce self-healing of P. c. 
chabaudi infection in male CD1 mice.
The aminopeptidase was purified by a combination of size- 
exclusion HPLC and affinity chromatography and, alternatively, by a 
combination of size-exclusion HPLC and anion exchange 
chromatography. The aminopeptidase activity appears to be composed 
of four different aminopeptidases with an apparent monomeric 
molecular weight range of 60 to 70 kDa.
Comparative studies of the inhibition of the P. c. chabaudi and 
porcine kidney aminopeptidase by bestatin indicate that the active site 
of the malarial aminopeptidase could differ to the mammalian 
aminopeptidase. Nucleotide probes/primers to clone this 
aminopeptidase(s) have been designed from the sequences of bestatin 
and metal ions binding site of several leucine aminopeptidases.
This thesis shows that the malarial aminopeptidase is a potential 
chemotherapeutic target with bestatin and/or bestatin analogues as 
potential antimalarial drugs. The difference between the binding site of 
bestatin on mammalian and malarial aminopeptidase could be exploited 
for the design of drugs that would be specific to the malarial parasite 
enzyme.
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Abbreviations.
AMC Amino methyl coumarin
BCIP 5'-bromo-4-chloro-3-indoyl phosphate
BSA Bovine serum albumin
DEPC Diethyl pyrocarbonate
DMF Di-methyl fluoride
DNA Deoxy ribonucleic acid
dNTP Deoxy nucleotide triphosphate
EDTA Ethylene-diamine-tetraacetic acid
FCS Foetal calf serum
HQ Hydrochloric acid
HI-FCS Heat inactivated foetal calf serum
IgG Immunoglobulin G
IPTG Isopropyl-b-D-thiogalactopyranoside
iv intravenous
K2HPO4 Di-potassium hydrogen phosphate
KH2PO4 Potassium di-hydrogen phosphate
LB Lauria Bertani
Leu Leucine
LF Lambda forward
LR Lambda reverse
Na2HP04 Di-Sodium hydrogen phosphate
NaCl Sodium chloride
NaH2P04 Sodium di-hydrogen phosphate
NaOH Sodium hydroxide
NBT Nitro blue tetrazolium
PAGE Poly acrylamide gel electrophoresis
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PBS Phosphate buffered saline
PCR Polymerase chain reaction
sc subcutaneous
SDS Sodium dodecyl sulphate
Tris Tris (hydroxymethyl) amino methane
X-gal 5-bromo-4-chloro-indoyl-Pgalactoside
RBC Red blood cells
WHO World Health Organisation
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Chapter 1 
General introduction
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1.0. Human malaria.
Malaria, meaning "bad air" was so named because of association of the 
disease with the odorous air of swamps, particularly at night. Although 
historians and economists have largely failed to recognise it, malaria 
must have played a large part in the history of the world and the 
progress of nations (Bruce-chwatt, 1988). While the disease is tolerated 
as a relatively uncommon infection in most economically rich countries 
it still ranks as a very important disease in various tropical countries in 
Asia, Africa and South America.
A programme to eradicate malaria in the economically rich 
countries came into operation in 1947, and by 1958 seventy six 
countries were planning, carrying out or had completely eradicated 
malaria (WHO, 1955, 1957 1967; Young, 1957; Williams; 1958; 
Bradley, 1966). The most successful eradication of malaria was 
obtained by the use of the organochlorine insecticide DTT which was 
subsequently banned in 1972 for ecological reasons. The use of 
insecticides thus targeting the Anopheles malarial vector is still 
recognised as one of the most efficient methods to eradicate malaria in 
the tropical countries which still suffer enormous deaths (up to two 
million each year) from malaria (WHO, 1955, 1957, 1967, 1996).
For centuries natives of regions where malaria is endemic have 
obtained remedies of malaria from a specific bark of a tree which was 
first introduced in Europe as "fever bark". Analysis of this bark 
showed that this remedy contained quinine and allied alkaloids. These 
alkaloids, especially quinine, remain among the standard treatments for
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malaria to this date. However, the increasing spread of Plasmodium 
falciparum resistant to nearly all existing anti-malarial drugs together 
with the absence of an efficient vaccine against malaria emphasises the 
urgent need for alternative eradication and treatment strategies 
(Maurice, 1995 and Tanner et al., 1995).
A "return to basics" strategy has been adopted by the WHO 
which is now promoting the use of bed nets as the major means of 
malarial control (WHO, 1996). The other strategy adopted is the search 
for new parasite targets and anti-malarial molecules. In this respect the 
past 20 years have witnessed a very impressive increase in our 
understanding of the biochemistry and molecular biology of the 
malarial parasite, with attention focused on specific parasite molecules 
that are keys to the parasite life cycle or the induction of it's 
pathogenesis. Directed pharmacology research has involved the 
identification and characterization of targets that can be specifically, 
pharmacologically affected, they include the replication machinery 
(Smeijsters et al., 1994; Chakrabati et al., 1993; Rubin et al., 1993; 
Deharo et al., 1995), protein and nucleotide synthesis (King et al.,
1987; Queen et al., 1989; Coomber et al., 1994; Rathod et al., 1994; 
Eakin et al., 1995), lipid metabolism required for membrane 
biogenesis (Holtz, 1977; Ancelin et al., 1985; Beaumelle et al., 1988; 
Vial et al., 1990; Vial & Ancelin 1992) and protease inhibitors of 
metabolic pathways such as those involved in haemoglobin degradation 
(Charet et a l, 1980; Vander jagt et al., 1983, 1984; Gyang et al., 1982; 
Schrevel et al., 1990; Goldberg, 1992; Breton et al., 1993; McKerrow 
et a l, 1993; Curley et al., 1994; Rosenthal, 1995). The latter pathway 
has already been validated as a susceptible target to antimalarials 
(Slater & Ceramil992). Complete characterization of the molecular 
structure of the target should allow attack of these molecules at novel
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and distinct sites with new drugs concepts. In addition, the design of 
structurally analogous molecules to new and existing antimalarials that 
are specifically active against the parasite and tolerable to the host, will 
be facilitated.
1.1. Classification.
The malaria parasite belongs to the subkingdom of protozoa's, it is 
classified as a microscopic unicellular organism although it undergoes 
schizogony to form multinucleated particles known as segmentors or 
schizonts during the intra-erythrocytic asexual life cycle. This Protozoa 
is also a Sporozoa as the formation of spores are included in it's life 
cycle.
Class: Telosporidae : The zygote undergoes sporogony to 
produce sporozoites which after entering a host become trophozoites, 
which multiply by schizogony and eventually produce gametocytes.
Subclass : Haemosporidae: Schizogony takes place in fixed tissue 
cells such as the spleen and liver in P. falciparum, with subsequent 
schizogony in erythrocytes. Gametocytes are found in red cells and 
fertilisation takes place in arthropod host (mosquito). The oocyst grows 
and produces many sporozoites. The asexual phase takes place in 
mammals and the sexual phase takes place in arthropods {Anopheles 
mosquito).
Order or family: Plasmodiida: Gametocytes are found in the red 
blood cells of vertebrates. Formation and syngamy of gametes takes 
place in arthropod host, the mosquito. Pigment granules (hemozoin) 
are deposited when the red cell is invaded.
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Genus: Plasmodium : Parasites of lizards, birds and mammals, 
gametocytes in red blood cells; erythrocytic schizogony; extra 
erythrocytic forms in various tissues, but always solid or at most 
vacuolated bodies; arthropod hosts mosquitoes.
1.2. Mammalian species of Plasmodium.
Typical species of malaria transmitted by mosquitoes, are found among 
mammals only in man and monkeys with the exception of three species, 
Plasmodium berghei, Plasmodium chabaudi chabaudi, and Plasmodium 
vinckei which are found in rats and various rodents. Both the primate 
and rodent parasites are transmitted by species of Anopheles only.
Apes and monkeys harbour a number of species which are 
closely related to the species found in man. Plasmodium rhodhaini of 
chimpanzees has identical pathology with Plasmodium malariae in 
humans and Plasmodium cynomolgi is very similar to Plasmodium 
vivax. Plasmodium knowlesi, which causes rapid, fatal infections in 
rhesus monkeys, causes relatively mild and temporary infections in 
man. These animal models have proved very useful in studies on the 
intra-erythrocytic stages of malarial parasites.
Rodent malaria P. berghei is similar in it's life cycle to P. 
falciparum and is widely used as an animal model for P. falciparum 
(Maegraith et al., 1952; Thurston, 1953; McNally, PhD. thesis 1994). 
Unlike P. falciparum, P. c. chabaudi has a synchronous life cycle and 
has proved very fruitful for stage specific study of the 
intraerythrocytic parasites. It has now been accepted as a suitable 
animal model for P. falciparum infections of human malaria (Taylor- 
Robinson, 1995).
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1.3. Species of Plasmodium which cause malaria in man.
P. falciparum is very prevalent in the tropics but does not thrive as far 
north as P. vivax malaria. It has a 40-48 hours intra-erythrocytic cycle 
in man. P. falciparum causes a much more dangerous disease than the 
other species but runs a shorter course without relapses, seldom lasting 
more than 8-10 months without re-infection (Shortt et al., 1951).
P. vivax is the most widely distributed species, being prevalent in 
both tropical and temperate zones. It has an intra-erythrocytic cycle of 
48 hours in man and is particularly likely to cause relapse (Coateney et 
al., 1948; Shortt et al., 1948)
P. malariae is also widely distributed in both tropical and 
temperate climates, but is much less common than either P. vivax or P. 
falciparum. It has a 72 hours intra-erythrocytic cycle in man and 
causes infections of many years duration.
P. ovale is very rare, though it has been found in such widely 
separate parts of the world as West Africa, South America, Russia, 
Palestine and New Guinea.
There is no animal reservoir for any of these human parasites 
except possibly chimpanzees for P. malariae. The Anopheles mosquito 
is the only vector that propagates malaria.
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1.4. Malaria the disease.
In general each malaria attack begins with a shivering chill, sometimes 
accompanied by convulsions so severe that the teeth chatter, goose flesh 
stands out and the bed rattles. The temperature will be found to be 
several degrees above normal and still going up. In the wake of the 
chill comes a burning and weakening fever, with violent headache and 
nausea and a temperature up to 42° C or higher. The fever period is 
followed by a period of sweating so profuse that the clothes or bedding 
may become wringing wet. The sweating gradually subsides, the 
temperature drops rapidly, often below normal, and after 6-10 hours 
the patient rests fairly easily until the next attack. The paroxysms of 
fever and chills which are caused by merozoite lysis of red blood cells 
continue every other day for up to 2 weeks or more. Then they become 
less pronounced, the parasites become sparse, the patient feels well and 
the temperature becomes normal. Sooner or later there are relapses, in 
which the intermittent chills and fevers begin again. When the relapses 
begin after the long latent period they occur repeatedly at intervals of a 
month or so. After these have subsided some strains apparently die out, 
but others may persist for years. The spacing and probability of 
relapses are, however, apparently influenced by dosage of sporozoites,; 
acquisition of immunity, and administration of drugs (Coatney & 
Cooper, 1948). It is commonly accepted that relapses after a long 
period may be brought on by such physiological shocks as exhaustion, 
childbirth, operations, alcoholic binges, etc.
In P. falciparum malaria the disease is quite different, primary 
infections are common in visitors to the hyper endemic localities. The
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paroxysm of chills and fevers are irregular due to the asynchronous 
life cycle of parasite, they last 12 or 14 to 36 hours, are severe in 
nature, and often occur daily, a fresh attack sometimes beginning 
before the previous one has entirely subsided. The attacks usually last 
8-10 days and then the temperature declines. In just a few days there is 
a series of paroxysms, perhaps even more severe, and these 
recrudescence then continue in declining severity every 10 or 12 days 
for about 6 or 8 weeks, after which they become more irregular, 
although the blood continues to be infective. In tropical malaria 
countries the re-infection is more or less continuous. Under these 
circumstances the infected persons become "carriers" harbouring a few 
parasites, possibly too few to be found in blood smears, and showing 
few symptoms or none at all.
A number of pernicious conditions may develop, in P. 
falciparum malaria. The tendency of corpuscules infected with P. 
falciparum to cling together results in clogging capillaries and 
preventing the proper flow of blood in vital organs (MacPherson et al., 
1985; Kern et al., 1989). In the brain this, as well as a direct toxic 
effect, leads to numerous symptoms, among them coma, hypoglycemia 
(White et al., 1993) and sometimes sudden death by a stroke. This 
cerebral malaria is responsible for a large fraction of malarial deaths. 
In some cases violent gastrointestinal symptoms resembling cholera, 
typhoid, or dysentry develop, and in others heart failure or pneumonia. 
The commonest complications in patients who die of malaria are renal 
failure, hyperparasitaemia, acidaemia, jaundice, cerebral malaria, and 
severe anaemia due to merozoite release from erythrocytes (Phillips et 
al., 1994; Molyneaux et al., 1989; Soni et al., 1996).
In typical cases of primary P. vivax infections, after completion 
of one or two pre-erythrocytic cycles in the tissues, the parasites invade
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the blood stream about 7-14 days after infection. The time of 
appearance of parasitised erythrocytes is usually a little shorter in 
falciparum infections and a little longer in P. malariae infections.
P. ovale infections are not prone to relapses and are more 
susceptible than any of the other species to drug treatment.
In P. malariae infections the paroxysms occur at 72 hour 
intervals, are milder and of shorter duration, recur more regularly, 
and the infections persist for a longer time.
The fact that the attacks most commonly occur between midnight 
and noon, instead of in the evening, is often useful in distinguishing 
malaria from other intermittent fevers, for P. vivax and P. malariae 
infections.
Some of the characteristic symptoms of malaria will be 
elaborated in this thesis, which will also show that some of these 
symptoms are correlated with the life cycle of the species of the 
malarial parasites in question. This thesis will only emphasise on the 
intra-erythrocytic stages of malaria parasites. For a more detailed 
reading on the liver stage, mosquito stage of malaria parasites and 
diagnosis see Chandler and Read (1960) and O'Donovan (1993).
1.5. Natural resistance to malarial infection.
In 1949 J. B. S Haldane suggested that heterozygotes for red cell 
disorders such as thalassemia might be protected against death from 
malaria. Since then it has been demonstrated that individuals with 
anaemias linked to genetically modified haemoglobin such as Hb S, Hb 
E and Hb C and other red cell genetic disorders such as the deficiency 
in glucose-6-phosphate dehydrogenase (Livingstone, 1985) display
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protection against clinical and severe malaria. Most red cell genetic 
defects represent, in effect, polymorphic genetic resistance to malaria.
The malarial parasite has an obligatory erythrocyte stage that 
generates gametocytes that complete the life cycle of the plasmodia 
parasite, which begins and ends in the Anopheles vector (fig. 1). 
Genetic resistance to P. falciparum may involve the merozoite invasion 
into the red cell to begin the erythrocytic stage; the intracellular 
growth of the parasite and the erythrocytic lysis that occurs in 
coincidence with the maturation and subsequent dispersion of 
merozoites.
World distribution of the red cells abnormalities which confer 
innate resistance to malaria are mostly found in malaria endemic 
regions (Weatherall, 1987), suggesting that these genotypes are 
naturally selected due to exposure to malaria
1.5.1. Red cell genetic defects involving resistance to 
merozoite invasion of the red blood cells.
(a) Red cells with mutations in surface blood group antigens.
Natural resistance to P. vivax infection has been linked to the Duffy 
blood group antigen (Miller et al., 1973). When human volunteers 
were exposed to mosquitoes infected with P.vivax (Miller et al., 1976) 
the results demonstrated that, Duffy negative individuals were resistant 
to the infection, while all the other volunteers fell sick 11 to 15 days 
after exposure. The Duffy antigen is a 35-43 kDa glycoprotein located 
on the surface of erythrocytes (Hadley et al., 1984). Duffy negative 
genotype individuals are resistant/ refractory to P. vivax infection
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because erythrocyte invasion is prevented by the absence of this 
glycoprotein.
The Duffy positive genotype is predominantly encountered in the 
Caucasian population and very rare in African descent populations 
among whom resistance to P. vivax infection is commonly encountered 
(Boyd & Stratmann-Thomas, 1993)
Polymorphic forms of glycophorins identified as blood groups 
also exhibit resistance to P. falciparum invasion. The cells showing 
complete absence of A-glycophorin (A) can be demonstrated to reduce 
invasion of P. falciparum significantly but not completely (Pasvol et 
al., 1982). This is a rare blood group ( only about 10 individuals are 
known to carry this genotype world wide). Red cells expressing 
hybrids of the genes specifying A and B glycophorins, show 50% 
reduction of invasion (Pasvol et al., 1982, 1989). The red cells that 
lack A and B glycophorins were tested with two P. falciparum strains 
7G8 and Camp (Hadleys et al., 1987). The former invaded with 50% 
efficiency, while the latter only at 20% of the control. These results 
raise the possible heterogeneity among P. falciparum malaria variants 
as to their red cell binding determinants (Mitchell et al., 1986). 
However none of the red cells containing different polymorphic forms 
of the glycophorins that have been demonstrated to reduce invasion 
emulate the Duffy system.
(b) Red cells with cytoskeleton abnormalities.
Cytoskeleton proteins are active participants in the process of 
merozoite invasion. The only known highly polymorphic red cell 
cytoskeleton abnormality is the Melanesian ovalocytosis. Ovalocytosis 
is characterised by red cells with axial ratios smaller than that of
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elliptocytes and there is no hemolysis associated with it. The underlying 
molecular defect is unknown at present, although the thermal 
deformation profile of these cells is abnormal (Kidson et al., 1981) and 
the expression of surface blood groups is altered (Booth et al., 1977. 
Deformability of these cells is deminished (Saul et al., 1984). These red 
cells are resistant to P. falciparum (Kidson et al., 1981) and P. 
knowlesi (Hadley et al., 1983) invasion although these two parasites 
bind to different receptors.
Another cytoskeleton defect that has been found to be resistant to 
malaria invasion is elliptocytosis due to either the absence of 
glycophorin C or band 4.1 as described by (Hadley et al, 1988; Shear 
et al., 1986). They have found dramatically decreased invasion of P. 
berghei and P. c. chabaudi in ankyrin/spectrin deficient mice.
1.5.2. Red cell abnormalities that involve the intracellular 
parasite growth period.
(a) Haemoglobin S-containing red cells.
Epidemiological and clinical studies suggest that heterozygote Ps gene 
carriers could acquire P. falciparum malaria but that they were 
partially protected from dying of the infection (Allison et al., 1954; 
Livingstone et al., 1971). Luzzato et al. (1970) showed that the sickle 
trait increased the probability of parasitised AS (heterozygotes for 
HbS) red cells being removed from the circulation. Accelerated 
morphological sickling occurs in AS red cells containing parasite ring 
forms. At conditions of low pH, which are particularly prevalent in the 
cytosol of late parasitised AS red cells (Friedman et al., 1978), HbS 
polymerises, generating many nucleation events, and thus assuring that
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none of the polymer domains becomes large enough to deform the cell; 
hence there is no apparent morphological sickling (Roth et al., 1988). 
Friedman et al. (1978) demonstrated that As cells at 17% oxygen 
sustained normally the growth of P. falciparum whereas an oxygen 
environment of 3% after two days of normal growth in 17% oxygen 
inhibited parasite growth and parasites subsequently died in a couple of 
days. These events were even more pronounced in Sc and SS cells 
showing a deoxygenated dependency parasite growth inhibition.
Similar experiments by Pasvol et al. (1980) confirmed these findings. 
These results suggest that there are at least two resistance mechanisms 
in AS cells. First the parasites may die during the ring stage if they 
induce sickling. Secondly their existence may be seriously hampered 
during deep vascular schizogony; venules bedecked with adherent 
parasitised cells become partially or totally obstructed, a situation that 
leads to hypoxia and low pH, conditions that favour sickling and in 
which the parasite does not thrive (Friedman et al., 1978).
The mechanism of parasite death in sickled AS and SS cells is not 
fully understood. Friedmann et al. (1978), first proposed two possible 
mechanisms applicable to AS cells: The loss of K+ accompanying 
sickling was detrimental in itself to parasites growth and the loss of 
water, concomitant with the loss of K+, would progressively increase 
HbS polymerisation (Friedman et al., 1979a).
Two mechanisms have been proposed for the killing of P. 
falciparum by increased intra-erythrocytic polymerisation of HbS. The 
sickle polymer is not a good substrate for the proteases of the parasites 
and the plasmodium will starve to death (Eaton et al., 1987) or/and the 
polymer interferes directly with some critical function of the parasite. 
The AS carriers might benefit from the retardation in the HbF to HbS 
and A switch (Weatherall et al., 1981) observed, in the critical first
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five years of life in which no immune defence mechanisms against 
malaria are in place.
(b) Haemoglobin E-containing red cells.
HbE is the most frequent single-base mutation (26 Glu->Lys) that 
leads to an abnormal haemoglobin. It is likely to be the most frequent 
haemoglobin mutation in the world. An intriguing observation has been 
reported by Bunaratvej et al. (1986) that EE and EA erythrocytes are 
phagocytised to a greater extent by human monocytes than are infected 
normal erythrocytes, suggesting that the surface of HbE-containing red 
cells is modified by the parasite differently from that of normal red 
cells. This mechanism, conceivably based on increased oxidative stress 
damage of the red cell membrane, could render the carriers resistant to 
malaria. Increased antimalarial antibodies in these individuals might 
signal frequent but benign infection, conducive to early immunological 
resistance and survival through a double protection mechanism.
(c) Haemoglobin F-containing red cells.
Red cells containing 100% HbF cord blood cells, blood cells from 
adults with hereditary persistence of fetal haemoglobin (HPFH) and in 
HbF containing cells from infants (1-30% HbF) retard P. falciparum 
growth in vitro (Pasvol et al., 1977). This HbF retardation of growth 
is mediated by an increase in oxidative stress. These findings may 
explain the decrease in parasitaemia observed in the first six months of 
life and could be a contributing factor to the advantages offered to the 
carriers of (3s, (3C and, particularly the thalassemia genes, which exhibit 
a significant retardation of the HbF switch-off that occurs in the first
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five years of life. This period is critical in the protection against 
infection, since immune mediated resistance is not yet effective.
(d) Haemoglobinopathies due to abnormal haemoglobin chain 
synthesis.
Disorders of globin synthesis are genetically and physiologically more 
complex than the single aminoacid substitution of haemoglobins. (3- 
thalassemias have variations in the levels of haemoglobins A2 and F as 
well as a variable decrease in the synthesis rate of the (3 chain, a- 
thalassemias exhibit a spectrum of changes: a clinical silent form (- 
a/aa), a form with slight or moderate anaemia and red cells 
hypochromia and microcytosis (-a/-a and — /aa), a form with moderate 
to severe anaemia (-a/--) and, finally a form that is lethal in-utero or at 
birth (-/--) (Pasvol et al., 1977). A number of theories concerning the 
manner in which thalassemias may inhibit malaria parasite growth 
include three groups of mechanisms: those that impair the nutrition of 
the parasite as intraerythrocytic iron deficiency in thalassemia (Nurse 
et al., 1979) interacting nutritional deficiencies (Brockelman et al., 
1983), and low cell indices (Allison et al., 1982). Those that involve 
increased susceptibility to oxidative stress damage (Allison et al.,
1982), increased vulnerability to cell mediated phagocytosis (Allison et 
al., 1983), and low pyridoxane-phosphate oxidase activity in 
thalassemias (Clements et al., 1981). Finally the elevation and 
persistence of fetal haemoglobin in infancy and early childhood 
(Clements et al., 1981; Lehmann etal., 1972)
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1.5.3. Resistance involving erythrocyte lysis
(a) Haemoglobin C-containing red cells.
Epidemiological evidence of the connection between HbC and malaria 
is largely lacking, except for the fact that this abnormal haemoglobin 
has been found in malaria endemic regions.
Friedmann et al. (1979a) found significantly decreased growth curves 
of P. falciparum in oxygenated CC cells but not AC cells. This finding 
was confirmed by Olson and Nagel (1986), who, working on the 
synchronised cultures in addition demonstrated that P. falciparum 
growth in CC cells is not significantly modified in low oxygen 
conditions nor is normal development restored when the cells are 
suspended in high intracellular K+ which interferes with K+ efflux and 
dehydration. The parasitised CC cells are very resistant to lysis 
compared to parasitised AA (normal) cells. Degenerative late schizonts 
are observed in day 4, an observation compatible with an incapacity of 
parasitised CC cells to complete their schizogony with merozoite 
release
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Figure 1. Life cycle of the malarial parasite in man and 
mosquito. (Drawing courtesy of Dr. Louis miller).
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1.6. Immunological response to malarial parasites.
1.6.1. Acquired immunity to malarial infection.
The immunity against malaria is highly specific and not only fails to 
protect against attack by other species, but sometimes even strains of 
the same species. In many cases as long as the parasites persist in the 
body in an exoerythrocytic reservoir, as in vivax and malariae 
infections, or are constantly being re-inoculated as in falciparum 
infections in the tropics, the immunity once developed is restimulated 
as soon as it begins to fail, and no clinical relapses can occur. However 
in many cases rapid formation of antibodies or phagocytes in response 
to a renewed stimulus does not occur and these individuals suffer a 
relapse before the body reacts.
Infants in hyper-endemic areas do not suffer as much as is 
sometimes thought from malaria infections, as they are passively 
protected by the presence of HbF and their mothers antibodies until 
they begin to develop some of their own.
Natural resistance to malarial infections include the absence of 
the Duffy antigen on erythrocytes against P. vivax or the possession of 
genetically modified haemoglobin against most known species of 
Plasmodium (see Section 1.5). Other host defences include non specific 
immunological defences which include direct cellular responses by 
macrophages and granulocytes and natural killer cells. In addition a 
humoral component is provided through the alternate complement 
pathway, which is antibody independent. (Roitt et al., 1989)
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However, the type of T cells involved and the mechanisms involved are 
still unclear. These T cells might control malaria by the production of 
cytokines such as IL-1. IL-1 subsequently activates cytotoxic immune 
responses which include the acute and chronic inflammatory response 
through production of acute-phase proteins by the liver, and stimulates 
the action of IgE on mast cells and fibroblast to produce acute-phase 
proteins which in turn can stimulate the alternative and classical 
complement pathways to produce vasoactive substances (fig. 2). The 
vasoactive substances alter vascular permeability and induce 
immigration of leukocytes and other effector cells such as, 
polymorphonuclear phagocytes, and granulocytes. This diapedesis 
induces T cytotoxic activation which is important in resistance to 
malaria.
T helper and delayed-type hypersensitivity mediator cells play 
central roles through their recruitment and activation of non-specific 
cytotoxic cells, such as phagocytes and natural killer cells, and by 
augmentation of the humoral response. Cytokine-activated 
macrophages display much more active and efficient responses to 
intraerythrocytic malarial parasites. They migrate to this area by 
chemotactic factors derived from parasite antigens or from antibody 
activated mast cells. Hence, the inflammatory response appears to be 
the main cell-mediated immune response by which intraerythrocytic 
malarial parasites are eliminated from the infected host.
Nitric oxide inhibits the development of the exo-erythrocytic 
cycle of P. berghei ( Mellouk et al., 1991), P.yoelli (Niissler et al., 
1991) and P. falciparum (Rocket et al., 1991) in vivo. Nitric oxide 
has been reported to play an important role in host control of the 
primary patent parasitaemia but not on recrudescent or re-infection 
parasitaemia of P. c. chabaudi in vivo (Taylor-Robinson et al., 1996).
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Cells in which nitric oxide can be produced in amounts sufficient to 
cause a physiological effect are either macrophages activated by INF-y 
(Marietta et al., 1988), TNF-stimulated endothelial cells (Kilbom et al, 
1990), or the T helper 1 subset (Taylor-Robinson et al., 1994). The 
secretion of nitric oxide over short range distances in a localised 
environment, such as the spleen and the liver may kill parasites 
directly. Alternatively, nitric oxide may have an indirect effect through 
its well-documented property of vasodilation (Moncada et a l, 1991)
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al., 1989).
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1.7. Treatment of malaria.
Malaria treatment chiefly involves the use of aminoquinolines, such as 
chloroquine and it's analogues, and a number of additional drugs, for 
the erythrocytic stage and chiefly primaquine for the exoerythrocytic 
stage. Newer compounds such as mefloquine, ghinghaosu (also known 
as artemisinine, artesune and artemether) and halofantrine are also used 
(fig. 3 & 4).
Only asexual erythrocytic parasites produce clinical illness. 
Hypnozoites (hepatic parasites) and gametocytes do not produce 
recognisable clinical symptoms. Antimalarial agents that inhibit the 
replication of the asexual erythrocytic cycle provide the most rapid 
clinical improvement.
Although toxic side effects are a major draw back in the use of 
primaquine it remains the most effective agent for the radical cure of 
P. vivax malaria (Wemdorfer et al., 1991; White, 1992) This drug 
interferes with the mechanism of chloroquine and should be 
administered subsequent to chloroquine treatment for P. vivax. (Van, 
1990). Recent electrocardiographic studies indicate that halofantrine is 
potentially deleterious because of its dose-related cardiac toxicity. 
However new prescription rules have been introduced since this 
discovery (Giudiceilli et al., 1996). Open comparison of artemether 
and mefloquine in uncomplicated P. falciparum hyperparasitaemia 
show that artemether produced a significantly higher parasite reduction 
in 24 hours and significantly shorter parasite clearance than 
mefloquine. Fever clearance times are similar. Although both drugs 
are well tolerated, mefloquine produces more episodes of abdominal
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pain with or without diarrhoea and vomiting (Sowunmi et al., 1996; 
Looareesuwan et al., 1996; Cardoso et al., 1996). Artemether may also 
reduce the length of coma in severe malaria (Watkins et al., 1996). 
Several antibiotics that inhibit protein synthesis (e.g tetracycline and 
doxycyclin and clindamycin) are often administered in combination 
with the antimalarial agents. Older agents that have wide use include 
quinine and quinidine.
Malaria pathogens are highly adaptable to chemical changes in 
their environment. Following introduction of a new drug, it can be 
anticipated that P. falciparum will develop resistance within a few 
years. At the moment, there is no agent that can offer protection 
against malaria in all regions of the world hence the need for novel 
chemotherapeutic drugs is acute. This thesis will suggest bestatin or it's 
analogues as one of these novel antimalarial agents.
1.7.1. Mechanism of action of some drugs used in the 
treatment of malaria.
(a) 4-aminoquinolines.
1. Chloroquine
The mechanism of antimalarial action of chloroquine and other 
4-aminoquinolines is still unclear. Several mechanisms have been 
proposed. In one, binding of chloroquine to ferriprotoporphyrin-IX, 
released from haemoglobin in infected erythrocytes, produces a 
complex that is toxic for plasmodial and RBC membranes (Chou et al., 
1980).
In a second, uptake and concentration of chloroquine into the 
parasites raises the pH of the intracellular acidic food vacuole. This pH
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increase damages the ability of the parasite to degrade haemoglobin and 
causes the characteristic morphological changes seen microscopically 
(Yayon etal., 1985).
The third suggestion was that the chloroquine target is a heam 
polymerase responsible for detoxification of the food vacuole by 
polymerising toxic heam into non toxic hemozoin. Chloroquine inhibits 
this heam polymerase causing toxic heam to accumulate in the acid 
vacuole thus killing the parasites (Slater & Cerami 1992).
2. Quinine, quinidine and mefloquine.
The mechanisms of action of quinine and mefloquine are thought 
to be similar to that of chloroquine. Quinidine also has some 
antimalarial properties. Both quinidine and quinine display potentially 
hazardous cardiac toxicity.
(b) Diaminopyrimidines.
1-Pyrimethamine and trimethoprim..
The diaminopyrimidines, such as pyrimethamine and 
trimethoprim, inhibit dihydrofolate reductase in malarial parasites. 
These agents are effective at concentrations far below those needed to 
inhibit the mammalian enzyme, so selectivity can be attained. Inhibition 
of parasite dihydrofolate reductase blocks the synthesis of 
tetrahydrofolate, a precursor necessary for the formation of purines, 
pyrimidines, and certain amino acids (Gero & O'Sullivan, 1990). 
Parasites exposed to these agents do not form schizonts in the red blood 
cells or liver. When a diaminopyrimidine is used with sulfonamide or 
sulfone, a synergistic effect is achieved by blockade of two steps on the 
same metabolic pathway (Triglia et al., 1994). Sulfonamide inhibits the
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synthesis of aminobenzoic acid (McConkey et al, 1994) to 
dihydropteroic acid while the diaminopyrimidine blocks the reduction 
of dihydrofolate to tetrahydrofolate (Cowman et a l, 1991).
The molecular mechanisms of the newer experimental 
ghinghaosu and halofantrine are not known. However, ghinghaosu and 
it's derivatives are endoperoxide-containing compounds which 
represent a promising new class of antimalarial drugs. In the presence 
of intraparasitic iron, these drugs are converted into free radicals and 
other electrophilic intermediates which then alkylate specific malarial 
target proteins (Meshnick et al, 1996).
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Figure 3. Drugs used to treat infection are effective against 
either erythrocytic or exoerythrocytic stages of the parasite. 
(Reproduced from Wingard et al., 1991).
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1.8. Haemoglobin and malarial parasites.
Haemoglobin comprises 95% of the soluble red blood cell proteins and 
is present at 340 mg/ml of blood. During the trophozoite stage the 
malarial parasites digest up to 75% of haemoglobin for use as a 
nutrient source in their growth and development.
A mouth like structure the cytostome sucks red blood cell cytosol 
into the parasites by a process resembling pinocytosis. These vesicles 
pinch off and carry their contents to an acidic digestive vacuole. The 
outer membrane of the double membrane bearing transport vesicle 
appears to fuse with the digestive vacuole and release a single 
membrane-containing vesicle inside. The vesicle is then rapidly lysed. 
Globin is degraded to aminoacids for use as the main source of amino 
acids for synthesis of parasite proteins (Moulder, 1962 & 1985) as 
shown by 14-c incorporation in parasite proteins from cell 
haemoglobin (Sherman et al. 1970). The heam is co-ordinated into a 
crystalline matrix called hemozoin or malaria pigment by a heam 
polymerase (Slater & Cerami, 1992).
Haemoglobin digestion is initiated in the acidic digestive vacuole 
by the aspartic proteases Plasmepsin I by cleaving native haemoglobin 
in the a  chain between Phe33 and Leu34. This site is in the hinge 
region of haemoglobin which is involved in maintaining the integrity 
of the molecule as it binds oxygen (Perutz, 1987). It is a highly 
conserved stretch of aminoacids in all vertebrate haemoglobins 
(Dickerson et al., 1983). None of the hundreds of characterised human 
variant haemoglobins have a homozygous defect in this region 
(Beutler, 1990) consistent with the notion that the parasite has found a 
way to attack the haemoglobin molecule at a site that cannot be altered
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without deleterious consequences to the host (Goldberg et al., 1991; 
Francis et al., 1994). Cleavage by Plasmepsin I appears to unravel the 
substrate after which major early secondary cleavages occur between 
aal05 and aal06 by Plasmepsin I and aal08 and aal09 by Plasmepsin
II. Plasmepsin II possibly cleaves native haemoglobin but cleaving 
activity was more enhanced on the denatured molecule. A cysteine 
protease degrades the unravelled haemoglobin molecule in both the a  
and P chains of haemoglobin. The cleavages that these enzymes make 
are infrequent enough that there must be exopeptidases to finish the 
proteolysis, generating free amino acids for the parasites nutrition. 
(Goldberg et al., 1991) This thesis describes malarial aminopeptidases 
that might be involved in proteolysis of haemoglobin derived peptides 
and shows that inhibition of these aminopeptidases by bestatin inhibits 
parasite growth.
1.9. Aminopeptidases.
Aminopeptidases are exoproteases which catalyse the cleavage of 
polypeptide substrates near the N-terminal extreme thus releasing free 
aminoacids or dipeptides. They can be subdivided into aminopeptidases 
which hydrolyse the first peptide bond (aminoacyl-peptide hydrolase 
and iminoacyl-peptide hydrolase) and those which remove dipeptides 
from polypeptides chains (dipeptidyl-peptide hydrolase). Some 
peptidases act only on dipeptides or tripeptides and may also be 
considered as aminopapetidases. They are widely distributed 
throughout the animal and plant kingdom. Generally, aminopeptidases 
are metalloenzymes and most of them require zinc as the metal 
cofactor for enzymatic activity. These enzymes generally have a broad
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specificity and can be monomeric or associated in protein subunits. 
Their specificities overlap, so that many natural and synthetic 
substrates may be hydrolysed by more than one enzyme.
They are involved in major regulatory process such as cell 
division enabling cells to pass critical check points by participating in 
proteolytic events essential for cell growth and viability (Constam et 
al., 1995) and in the regulation and metabolism of neurotransmitters 
(which has been associated to aminopeptidase-N) within the neural cells 
and the gastrointestinal tract indicating the implication of 
aminopeptidases in pain transmission (Akasaki et al., 1995; Konkoy et 
al., 1995, Stevens et al., 1995). Down regulation of cell surface 
molecules such as interleukin receptors on neutrophils has been 
associated with aminopeptidase N (Manna et al., 1995) and hydrolysis 
of leukotriene A4 into chemotactic leukotriene (Baker et al., 1995, 
Watterholm et al., 1995) has been associated with aminopeptidase 
activity indicating the role of aminopeptidases in immunomodulatory 
activities. Aminopeptidase B-type activity has been localised in rat testis 
indicating a role in spermatogenesis (Cadel et al., 1995). Alanine 
aminopeptidase activity has also been associated with transport of 
oligopeptides into kidney brush border membrane vesicles (Daniel et 
al., 1995) and in the regulation of transcription in tomato leaves 
(Schaller et al., 1995).
(a) Classification.
Aminopeptidases are classified by the number of amino acids cleaved 
from the NH2-terminus of substrates and are given the numbers 
EC.3.11-3.4.13. Classification is also performed with respect to the 
relative efficiency with which residues are removed. Hence Leucine
34
aminopeptidase prefers leucine peptide substrates although activity with 
other substrates is observed. Arginyl, methionyl, aspartyl, cystynyl, 
prolyl, glutamyl and alanyl aminopeptidases have been described. With 
respect to location of the aminopeptidase, some peptidases are secreted, 
but most are not. Aminopeptidases are also classified by susceptibility 
to selective aminopeptidase inhibitors, according to the metal cofactors 
and/or the residues that bind the metal co factor to the enzyme and 
finally according to the pH at which maximum activity is observed to 
denominate acidic, basic, and neutral aminopeptidases.
Zinc aminopeptidases constitute the largest, or at least the most 
studied type, of aminopeptidases. They constitute a relatively large 
subdivision of the mammalian cell surface peptidase family. 
Identification of a new family of aminopeptidases evolved after recent 
work demonstrated that aminopeptidases from diverse organisms show 
extensive primary sequence homology (Burley et a l, 1992; Wood et 
a l, 1993)
1.9.1. Aminopeptidases in malarial parasites.
As described above (Section 1.8) the malarial parasite requires 
aminopeptidases in order to finish proteolysis of haemoglobin derived 
peptides into free aminoacids for protein synthesis. Aminopeptidase 
activity has been described in P. falciparum and rodent malarias by 
different research groups. However, some very important physical- 
chemical properties differ to such an extent that it would be best to 
describe the aminopeptidases characterised by different groups 
separately.
35
a) Aminopeptidases in rodent malarial parasites.
Aminopeptidase activity was first described in rodent malarial parasites 
by Charet and co-workers (1980) from P. c. chabaudi and P. yoelii 
nigeriensis early trophozoite cytosolic extracts. The aminopeptidase 
from the P. c. chabaudi trophozoite extracts had an apparent molecular 
mass of 90 kDa. determined by non-reducing gel filtration and a Km = 
0.7 mM ± 0.2 with L-alanyl-4-nitroanilide. This enzymatic activity was 
highly inhibited by Zn2+ and more slightly by Co2+ and Mn2+ ions. 
Iodoacetamide and cysteine were without effect, but PCMB and Hg2+ 
were strong inhibitors. The optimal pH activity and temperature were
7.2 and 50°C respectively. Electrofocusing studies revealed that the 
aminopeptidase activity peak was composed of four different pi values 
(5.85, 5.7, 5.6 and 5.5) suggesting four different aminopeptidases with 
the same apparent molecular mass. The aminopeptidase activity was 
also strongly inhibited by chloroquine, quinacrine and primaquine 
whereas quinine had a smaller effect. Aminopeptidase from P. yoelii 
nigeriensis showed the same apparent molecular mass of 90,000, Km =
1.4 mM ± 0.2, pH optimum of 7.2, pHi 5.2, 5.3 and 5.4. The optimal 
activity for this enzyme was observed at 37°C (Charet et a l, 1980).
Curley et al.,(1994) described aminopeptidase activity observed 
in cytosolic cell-extracts from each intra-erythrocyte stage of P. c. 
chabaudi and P. berghei with most activity being detected in early 
trophozoite. Comparative study of the aminopeptidase activity in each 
extract revealed that the enzymes had similar specificities and kinetics 
with substrate L-leu-AMC, Km = 56 and 26 |jM, Vmax = 26 and 56 
nMol/min/mg protein for P. berghei and P. c. chabaudi, respectively a 
near neutral pH optimum of 7.2 and are moderately thermophilic (P.
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chabaudi 50°C and P. berghei 45°C). The molecular weight of the 
enzyme from P. c. chabaudi and P. berghei extracts was estimated at 80 
± 10 kDa determined by HPLC. Both aminopeptidases were shown to 
be metallo-proteases but zinc did not appear to be the metal cofactor as 
with other aminopeptidases. However Ca2+ restored up to 50% of the 
original activity when added to the apoenzyme at 50 )iM. The 
preferred synthetic substrate for the aminopeptidases was L-leu-AMC 
and L-ala-AMC. The enzymes were completely inhibited by bestatin 
but not leupeptin. O -phenanthroline was a strong inhibitor while 
aspartic-cysteine- and serine protease inhibitors had little or no effect, 
Mn2+> Hg2+ and Cd2+ were strong inhibitors whereas Zn2+ and Mg2+ 
were weak inhibitors (Curley et al., 1994).
Ultrastructural localisation studies in P. c. chabaudi by 
Slomianny et al.,(1983) detected aminopeptidase activity first at the 
level of cytoplasmic ribosomes where the aminopeptidase is 
synthesised. The activity then migrates and is found associated to the 
membrane of pinocytotic vesicles as soon as these were formed. The 
labelling then extends to the vesicle contents where it becomes very 
prominent. This enzyme activity was detected in the ring stage and 
early trophozoites In late trophozoites enzymatic activity decreased 
and was no longer detected (Slomianny et al., 1983).
(b) Aminopeptidases in P. falciparum.
Gyang et al. (1982) described P. falciparum aminopeptidase activity 
with an apparent molecular mass of 186 kDa by gel filtration, pH 
optimum of 7.5, pi = 6.05 and apparent Km = 2.2 mM with L-alanyl-p- 
nitroanilide. The aminopeptidase was completely inhibited by 1 mM 
Hg2+, Zn2+ and Cd2+. Leupeptine inhibited the aminopeptidase.
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Vander jagt and co-workers described aminopeptidase activity 
from P. falciparum chloroquine resistant and sensitive trophozoite 
extracts. The purified enzyme had a molecular weight of 100 kDa ( 
Vander jagt et al., 1984). However a combination of gel filtration and 
hydroxylapatite revealed aminopeptidase activity at approximately 63 
kDa. (Vander jagt et al., 1987). This enzyme also preferred L-leu- and 
L-ala- peptide substrates and was inhibited by bestatin and 
phosphoramidone but not leupeptine. pH-rate studies indicated the 
presence of a sulfhydryl group on the free enzyme, pKa = 6.6, which 
must be in the conjugate base form for activity. This essential 
sulfhydryl group at the active site (Fulton et al., 1956) was rapidly 
modified by Hg2+ and Zn2+> and was slowly modified by p- 
hydroxymercuribenzoate, but was not accessible to iodoacetamide or 
N-ethylmaleide. This aminopeptidase activity was inhibited 
noncompetitively by chloroquine (Kj = 410 and 535 |XM) for the 
resistant and sensitive strains respectively, mefloquine and quinacrine 
(Ki = 280 and 20 |iM, respectively), but was not inhibited by quinine 
or primaquine.
Curley and co-workers (1994) showed that the aminopeptidase 
from P. falciparum extracts had a slightly higher molecular weight 
than the enzyme from P. c. chabaudi and P. berghei extracts but 
presented the same physical properties. The enzyme was not inhibited 
by Mg2+ unlike the rodent aminopeptidases which showed up to 50% 
inhibition. All the P. falciparum aminopeptidase activities described so 
far show maximum activity at near neutral pH of 7.2 and the optimum 
temperature for activity is 50-60°C.
Aminopeptidases are increasingly being investigated as 
therapeutic targets in various diseases, some results of these 
investigations will be reported in section 1.10.3-1.10.9. The P. c.
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chabaudi aminopeptidase described by Curley et al., (1994) will be 
purified and characterised in this thesis. It will be compared to the 
other aminopeptidases to try and determine whether there is a single or 
four aminopeptidases. The binding kinetics of the aminopeptidase 
inhibitor bestatin and nitro-bestatin will be investigated and compared 
to the binding kinetics of bestatin to malarial aminopeptidases, cloning 
of this aminopeptidase will also be investigated. The purification and 
characterisation will enable a better understanding of the mechanism of 
action of malarial aminopeptidases, allow chemotherapeutic studies 
directed at this enzyme and vaccine trials using the purified 
aminopeptidase.
1.10. Bestatin.
Bestatin [(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]-L-leucine 
(fig. 5) was discovered by Umezawa et al., in 1976 from culture 
filtrates of Sreptomyces olivoreticuli while in search for low molecular 
weight inhibitors of aminopeptidase-B on the surface of cells. Bestatin 
has attracted considerable attention since it's discovery due to it's 
numerous biological activities, most notably as an immune response 
modifier (inflammatory response) and a potential analgesic. It is now 
widely known that bestatin inhibits most known aminopeptidases with 
variable rates and affinity but not aminopeptidase-A (Nishizawa et al., 
1977). This characteristic of bestatin offers new opportunities to 
identify and characterise the bestatin-binding site which is presumably 
the active site of susceptible aminopeptidases. There are three reactive 
functional groups, NH2, OH, and COOH, in the bestatin molecule.
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Bestatin
Figure 5. Structure of bestatin (Suda et al., 1976).
1.10.1. Inhibition of aminopeptidases by bestatin and 
bestatin analogues.
Bovine lens leucine aminopeptidase is the aminopeptidase of which the 
bestatin binding site has been researched the most. Studies investigating 
the active site using bestatin show that the bestatin-binding sites of 
bovine lens leucine aminopeptidase were found within the unique, large 
tryptic and the small hydroxylamine polypeptide, both of which are 
located within the carboxylic third of the subunit. The peptide chain 
length also is an important contributor to both the slow binding 
properties of bestatin and the related inhibitor amastatin and to the 
preferential binding of bestatin and amastatin to different 
aminopeptidases. This was corroborated by NMR and crystallographic 
data, which indicated that the phenylalanyl side chain of bestatin is 
bound to a hydrophobic pocket comprised of met-270, Thr-359, Gly- 
362, Ala-451 and Met-454 and that the leucyl side chain binds to 
another hydrophobic cleft formed by Asn-330, Ala-333 and Ile-421 
(fig. 7, Taylor A, 1993). When bound to the enzyme, the backbone of
bestatin is stabilised by hydrogen bonds involving Lys-262, Asp-273 
and Leu-360 (Taylor, 1993). Bestatin is a slow tight-binding inhibitor 
for most of the aminopeptidases tested to date. The slow binding 
involves rapid formation of the enzyme-inhibitor (El) complex slow 
transformation of the El to the tighter complex El , and even slower 
deformation of that complex. There is little conformational change 
resulting from the binding of bestatin to blLAP. Structure modification 
studies of bestatin have established that the presence of the 2(s)- 
hydroxyl group is important for tight binding to aminopeptidases (Rich 
et al., 1984). The structural relationship between bestatin's critical 
2(s)-hydroxyl group and a probable tetrahedral intermediate for amide 
bond hydrolysis led to the idea that bestatin might be a transition state 
analogue inhibitor of aminopeptidases in which the sp3 geometry and 
alcohol at the C-2 carbon of the inhibitors mimics the tetrahedral 
intermediate formed during substrate hydrolysis. Nishizawa et al., 
(1977) suggested that an essential, active-site zinc ion is chelated by the 
2(s)-hydroxyl group and the 3-amino group when bestatin is bound to 
aminopeptidases (fig. 6 A). An alternative in which the C-2 hydroxyl 
group and the amide carbonyl bound to the active site zinc was 
postulated (fig 6. B; Nishino et al., 1979). Both mechanisms suggest an 
interaction between the 2(s)-hydroxyl group and the zinc ion presumed 
to be present in the active site of aminopeptidases. Another point that 
needs clarification is why some substrates, or substrate components 
stimulate rather than inhibit aminopeptidase activity.
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A B
Figure 6. (A) Mechanism of inhibition of aminopeptidase by 
bestatin as proposed by Nishizawa et al.,(1977). (B) Mechanism 
of inhibition of aminopeptidase by bestatin as proposed by 
Nishino & Powers, (1979).
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Figure 7 Proposed mode of inhibition of bovine lens leucine 
aminopeptidase by bestatin. (a), and peptide hydrolysis (b) & (c) 
as proposed by Burley et al. ,  (1992)
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1.10.2. Structure-activity relationship of bestatin and 
analogous compounds.
Structure activity relationship of bestatin and some related compounds 
are an important factor in the investigation of the antimalarial activity 
of bestatin. Bestatin analogues modified on the amino, hydroxy and 
carboxylic (bestatin amides, N-benzyloxycarbonyls) groups were weak 
inhibitors of aminopeptidase suggesting that the free amino hydroxy, 
and carboxylic groups were essential for the inhibiting activity of 
bestatin. Aminopeptidase activity of the eight stereoisomers of bestatin 
indicate that the configuration at C-2, but not that of C-3 is the most 
important factor for the manifestation of activity and the 
stereochemical requirements for the other asymmetric carbon atoms 
with regard to activity are not very strict (fig. 8; Nishizawa et al., 
1977). It was also shown that the effects of different bestatin analogues 
varies with different aminopetidases. The activity of the stereoisomers 
against aminopeptidase-B did not correlate exactly with that against 
leucine aminopeptidase (Nishizawa et a l , 1977). Other experiments 
showed that the S configuration at C-2 is a requirement for enzyme 
inhibition, hence the hydration of the carbonyl group is stereospecific. 
When the leucine moiety of bestatin was substituted, the compound in 
which the amino group was a  to the carboxyl group (2) showed most 
activity. This result suggests that the distance between the amino and 
carboxylic groups is important for enzyme inhibition. The importance 
of the S configuration of C-2 was confirmed by substituting the benzyl 
group of bestatin (Nishizawa et al., 1977).
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Figure 8 Structure of [(21S,,3/?)-3-amino-2-hydroxy-4- 
phenylbutanoyl]-L-leucine, R= CH2CH(CH3)2.
The importance of synthetic analogues of bestatin was 
demonstrated when the activity of ^ -nitro-bestatin IC50 = 0.01 (ig/ml 
(fig. 9) was found to be five times stronger than bestatin IC50 = 0.05 
|0,g/ml with (2S,3R)-/?-methylbestatin IC50 = <0.01 |ig/ml being the 
most active of the compounds (Nishizawa et al., 1977). Both these 
compounds contain a single addition of a nitro and methyl group on the 
phenyl ring respectively.
h3c 'x " ^ n
H  O H
p -nitro-bestatin
o
H 3C
h 3c "
O H
0  r
'  N i l
H  O H
p-methyl-bestatin
Figure 9. Structure of nitro-bestatin and methyl-bestatin.
Ocain et al. (1988) replaced the C-2 hydroxyl group in the 3- 
amino-2-hydroxy-4-phenyl-butanoic acid (AHPBA) with a thiol group 
in order to capitalise on the high affinity of sulfhydryl groups for zinc 
ions (fig. 10). Aminothiols, L-leucine thiol (2) and L-lysinethiol (3) 
and the corresponding alcohols (2a & 3a) were synthesised for these 
studies. Additionally, replacement of the bestatin amide carbonyl with a 
thiocarbonyl group was investigated for it's affinity for the active-site 
zinc ion. Thiol bestatin (4) and thiolamides (5) were synthesised for 
this study.
H  X - H
C-2 thiolbestatin 4, X= S; Y = O 
C-2 thiolamide bestatin 5, X= O; Y = S
Figure 10. Replacement of the C-2 hydroxyl group in AHPBA.
The 2-thiol bestatin (4) was only 2-fold more potent than 
bestatin for the inhibition of aminopeptidase-M (AP-M) and only 13 
times more potent than bestatin for inhibition of aminopeptidase-B
L-leucinethiol 2, X = S 
3a, X = O
L-lysinethiol 3, X = S 
3a, X = O
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(AP-B). Thiol-bestatin (4) was significantly weaker as an inhibitor of 
LAP. It is the aminothiols, leucinethiol (2) and lysinethiol (3), that 
show the most pronounced benefit for AP-M and AP-B. The thiol 
compounds were actually poorer inhibitors of LAP. All thiolamides 
were significantly poorer inhibitors than the amide counterparts for all 
three enzymes (Ocain et a l , 1988)
This thesis will investigate the binding kinetics of bestatin to 
malarial aminopeptidase extracted from P. c. chabaudi early 
trophozoites and compare the results to the porcine kidney mammalian 
aminopeptidase. The effects of some bestatin analogues on malarial 
aminopeptidase activity will also be investigated.
1.10.3. Immunomodulatory effects of bestatin in vitro.
Bestatin has been shown to have immunomodulatory effects, 
presumably through the inhibition of multiple aminopeptidases, 
including the augmentation of humoral and cell mediated immune 
responses and the activation of macrophages and natural killer cells.
The activation of macrophages was dose dependent in vivo , 
cytotoxicity of macrophages was observed at concentrations of bestatin 
less than 50 |ig/ml with this concentration being the optimum. At 
concentrations greater than 100jig/ml macrophage, cytotoxicity was 
inhibited. A dose dependent adjuvant-like activity was also observed 
(Talmadge et al., 1986). IL-8, a neutrophil chemotactic agent, is known 
to have an active role in the induction of the inflammatory response in 
a number of diseases. The IL-8 receptor on the surface of neutrophils 
are very quickly down regulated, up to 85% of the receptor's activity 
is lost within 90 min of incubation at 37°C. This down regulation is 
almost completely prevented by bestatin at 40|xM (Manna et al., 1995).
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Bestatin at 0.1 (im/ml was found to increase the number of the 
nucleated mature cells and that of the myeloid progenitors in long term 
bone marrow cultures (LTBMC) from the non-adherent layer versus 
controls. The total number of colonies and the number of myeloid 
progenitors but not that of erythroid progenitors from the adherent 
layer was also increased following treatment with bestatin at 1.0 
p,M/ml. This stimulation of the production of mature cells and myeloid 
progenitors on normal hematopoiesis by bestatin in LTBMC was 
mediated by an indirect action via IL-6 production (Fujisaki at al., 
1995). The mechanisms involved in the anti-tumour effects of bestatin 
were investigated on breast cancer cells line YMB-S. These cancer cells 
proliferate in a floating manner without aggregation in normal 
complete medium. Bestatin induced cell-cell and cell-surface adhesion 
of the cells accompanied with growth suppression. No increase in E- 
cadherin localised at cell-cell contact sites was observed between 
bestatin treated cancer cells and control cancer cells. Indicating that 
bestatin inhibits the proliferation of YMB-S cells and augments cell-cell 
adhesion through the induction of E-cadherin-mediated adhesion 
resulting from the functional activation of pre-expressed but inefficient 
E-cadherins (Fijioka et al., 1995).
1.10.4. Therapeutic effects of bestatin in vivo .
Bestatin has been shown to activate peritoneal macrophages in vivo . 
This in vivo activation of macrophages was confirmed using tumour 
cells as targets (Schrlemmer et al., 1983). Bestatin has been shown to 
have some therapeutic effects against muscular dystrophy in mice 
(Satoyoshi et al., 1992) although clinical trials with duchenne muscular 
dystrophy patients failed to prove these effects (Hirano et al., 1994).
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Tsuruo et al., (1981) found bestatin to suppress the gradually- 
occurring lymph node metastasis of P388 leukaemia in CDF1 mice 
when administered intra-peritoneally at doses of approximately 30 
(ag/mouse. Bestatin could not, however, suppress the established large 
metastasis of P388 leukaemia. Bestatin prolonged survival time in 
Candida albicans infected normal mice in a dose dependent manner. In 
immunosuppressed mice, bestatin at 5 mg/day significantly increased 
the number of survivors. These results suggested that bestatin was a 
potent biological response modifier for prevention against 
opportunistic infections (Coppi et al., 1994). The combination of IL-8 
with bestatin induced cervical ripening in rabbits by providing 
approximately regular levels of neutrophil numbers, collagenase and 
elastase activities. It has been suggested that this regulatory mechanism 
also takes place in vivo through the inhibitory effects of bestatin on 
aminopeptidase N activity (el Maradny et al., 1995).
1.10.5. Clinical trial using bestatin as a therapeutic tool.
Several trials have been carried out using bestatin as a therapeutic tool 
in various diseases where aminopeptidases were thought to play a 
critical role. Clinical trials show that in order to obtain a therapeutic 
effect bestatin must be administered in large doses. This requirement is 
shared with other polypeptides such as muramyl dipeptide, 
enkephamids, tuftsin and small proteins such as interleukin 2 and the 
interferons. Presumably these small proteins and peptides are subject to 
proteolysis by plasma and tissue proteases. Pilot clinical studies with 
bestatin orally administered at 150 mg/body twice per day, twice per 
week, for at least 8 weeks showed that the plasma half life time of 
bestatin was 2.1 ± 0.7 hours and the total urinary recovery was 71.4%
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in 48 hours. Among 8 patients with myelodysplastic clinically studied, 
one achieved good response and another achieved minor response 
(Ueda et al. 1994). Bestatin was suggested as a new approach to treat 
chronic myelogeneous leukaemia (CML) in combination with busulfan. 
Twenty three patients with Phase 1 positive CML, including 20 in the 
chronic phase and 3 in the accelerated phase, were treated with the 
combination therapy. Complete hematologic remission was obtained in 
all patients, complete cytogenetic response was obtained in 6 patients, 
partial cytogenetic response in 1 patient and minor cytogenetic 
response in 6 patients. Cytogenetic conversion to a normal diploid state 
persisted for 6-41 months. Three year survival was 86.6%. Therefore 
bestatin effectively controls chronic myelogeneous leukaemia (Uzuka et 
al., 1993) and is now being used for treatment of acute non-lympocytic 
leukaemia (Takeuchi et al, 1995). Bestatin is a potentially useful 
treatment in patients with rheumatoid arthritis (Aoyagi et al., 1981 & 
1990).
This thesis investigates the antimalarial potency of bestatin on P. 
c. chabaudi and on both chloroquine resistant and chloroquine sensitive 
P. falciparum strains in culture. An in vivo antimalarial potency of 
bestatin will also be investigated with P. c. chabaudi infected CD1 
mice. This thesis also investigates the effects of some bestatin analogues 
on aminopeptidase activity. Indeed, a non-hydrolysable bestatin 
analogue could prove a better antimalarial as it would not need to be 
administered in such large doses and as frequently as bestatin has to be.
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1.10.6. Induction of analgesia by bestatin.
Aminopeptidases are thought to play a critical role in the metabolism 
of endogenous opioid peptides. Inhibition of the proteolysis of opioid 
peptidases by aminopeptidase inhibitors has been reported to induce 
analgesia. Aminopeptidase M activity has been reported to be 
implicated in the proteolysis of endogenous opioid peptides such as 
Dynorphin A (Muller et al., 1995) and met-enkephalin. A cocktail of 
aminopeptidase inhibitors including bestatin protected met-enkephalin 
from degradation in caudate putamen (Konkoy et al., 1995). The 
peptide drug met-enkephamid is an analog of natural met-enkephalin. 
When gastrointestinal absorption of this drug was investigated, most of 
the met-enkephamid administered to the jujunal loop was degraded in 
the lumen by enzymatic hydrolysis and only 0.3 to 1.2% of the drug 
was absorbed into the vascular flow. Co-administration of the peptide 
drug Met-enkephamid with bestatin effectively increased 
gastrointestinal absorption of this peptide drug by supressing it's 
degradation (Taki et al., 1995). Counterirritants such as 1-menthol 
which show a major effect in the early phase of pain response are 
widely used in the treatment of mild pains and itches by topical 
application. The induction of this counterirritant was potentiated by 
bestatin (Tanaguchi et al., 1994).
The aminopeptidase inhibitor bestatin inhibits proteolysis of 
endogenous and synthetic opioid peptides thus increasing the half-life 
time of the opioid peptides and hence their absorption in the 
gastrointestinal tract (Muller et al., 1995; Konkoy et al., 1995). It can 
be suggested that bestatin induces analgesia by increasing the 
bioavailabilty of synthetic and endogenous opioid peptides. Bestatin
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could also induce analgesia via the modulation of endogenous, 
exogeneous and synthetic opioid receptors. This induction of 
antinociceptive stimuli by bestatin could prove beneficial in the 
treatment of malaria symptoms.
1.11. Plasmodium chabaudi chabaudi.
P. c. chabaudi was first described in thicket rats as a rodent malaria 
species similar to P. vinckei (Landau, 1965). Ten years later Carter & 
Williker (1975) characterised P. c. chabaudi parasites as having a 
synchronous development, with a 24 hours asexual life cycle and 
schizogony occurring around midnight. This life cycle is biologically 
linked to light exposure.
Analysis of parasitaemias in infected mice when reticulocytosis 
was induced by phenylhydrazine treatment showed that the course of P. 
c. chabaudi infection was altered, in that lower parasitaemias were 
reached in mice treated with phenylhydrazine prior to infection (Ott, 
1968). Erythrocyte invasion of the parasites was hence first attributed 
to a preference of mature erythrocytes as reticulocytes were invaded 
by P. c. chabaudi parasites when the circulating normocytes population 
had been depleted by rupturing parasites (Carter & Walliker 1975). 
However Jarra & Brown (1989) again using phenylhydrazine treatment 
of infected mice, found that the invasive behaviour of the parasites in 
vivo reflected the availability of erythrocytes of different ages, with no 
preference for either mature erythrocytes or reticulocytes.
Since the first description of P. c. chabaudi a number of wild 
strains have been isolated and new clones have been created. P. c. 
chabaudi AS strain is one of the cloned lines. This strain has a 24 hours
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asexual synchronous cycle with schizogony beginning around midnight 
The asexual cycle will be described in detail in this thesis. The 
beginning of schizogony can be altered by reversing the night and 
daylight times to which the infected mice are exposed.
1.11.1. Sequestration of P. c. chabaudi parasites.
P.c.chabaudi AS strain shows partial sequestration, the major site of 
sequestration being the hepatic sinusoid (Cox et al., 1987). This feature 
is shared by P. falciparum the only human malaria parasite to 
sequester, undergoing deep vascular schizogony. Significant proportion 
of this sequestration takes place in the post capillary veinular 
endothelium of the brain, where the parasitised erythrocytes can cause 
obstruction in the blood capillaries resulting in cerebral malarial 
(McPhearson et al., 1985)
1.11.2. Recrudescence of P. c. chabaudi infections.
Recrudescence is another feature of P. c. chabaudi, and has been 
associated with a decline in the effector arm of the immune response 
and also with the capability of the parasite to undergo antigenic 
variation (McLean et al., 1982a & b). This recrudescence arises from 
erythrocytic parasites which have survived after the host's immune 
response has cleared the majority of the parasites. Phenotypic variation 
is a feature shared by all human malarial parasites as a means to avoid 
the host's immune system, resistance to chemotherapy and vaccination 
(Cox, 1962; Brown & Brown, 1965; Voller & Rosan, 1969; Hommel et 
al., 1983).
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1.11.3. Protective immunity against P. c. chabaudi infection.
It is known that protective immunity is predominantly directed against 
the blood stages of the malarial parasite (Cohen & Lambert, 1982; 
Martinez, 1987). The spleen represents one of the major defence 
organs against blood stages of P. falciparum (Wyler, 1983). P. c. 
chabaudi is a convenient model to study protective immune mechanisms 
directed against blood stages of malaria (Schmitt-Wrede et al., 1991) 
There is documented evidence that these mechanisms are critically 
dependent on the sex of mice due to the circulating levels of 
testosterone (Wunderlich et al., 1988; This thesis).
Testosterone (Te) has been documented to increase susceptibility 
of vertebrate hosts towards many different protozoan parasites. A 
crucial role of Te has been documented in the outcome of murine 
malaria caused by P. c. chabaudi (Wunderlich et al 1988) and P. 
berghei (Kamis & Ibrahim, 1989). Female mice of the inbred strain 
C57B1/10 are capable of self-healing P. c. chabaudi infections.
However this same infection is lethal to male mice. The capability of 
self-healing P. c. chabaudi infection in male mice becomes evident after 
castration. On the other hand, P. c. chabaudi infection can be rendered 
lethal to female mice by pre-treatment with testosterone (Wunderlich et 
al., 1988). Female mice thus exhibit protective immunity against P. c. 
chabaudi infection. Once this protective immunity is established it is no 
longer responsive to Te-treatment. This Te-unresponsive protective 
immunity is mediated by spleen cells, presumably non-T-cells 
involving IgG secreting B cells (Wunderlich et al., 1992).
Host immunity to P. c. chabaudi shows sequential appearance of 
first Thl type cells early in infection followed by Th2 type cells later
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in the infection (Langhome et al, 1989a&b). It has also been showed 
that macrophages from P. c. chabaudi AS-infected A/J susceptible mice 
exhibit defects in oxygen metabolism and la antigen expression which 
may contribute to the susceptibility of these hosts to this intra­
erythrocytic parasite (Stevenson et a l, 1992).
1.11.4. P. c. chabaudi as an animal model for human 
malaria.
P.c.chabaudi is now widely accepted as a model for P. falciparum 
human malaria (Taylor-Robinson, 1995). The synchronous 
development of P. chabaudi enables research to be performed with 
homogenous parasite populations obtained directly from the mice 
without recourse to in vitro culturing, and parasites can be obtained at 
a specific time of day to suite the requirements of the researcher. 
Stage-specific drug targeting studies and comparative studies of lethal 
and non lethal infections of P. chabaudi AS were performed. The 
species is not contagious to humans hence it is safe to manipulate.
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Chapter 2 & 3 
Materials and methods.
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2.0-Materials.
Aldrich chemical Co.
Triton@X-100.
Becton-Dickinson and Co.
Microlance needles,
Plastipak syringes.
Biological Laboratories
CD1 and Balb/c mice , New Zealand white rabbits.
Chancer Propper
Gold Star microscopic slides.
Dupont
3H-Hypoxanthine, 35S-Methioninine.
Flow Laboratories
Foetal Calf Serum, L-glutamine
Greiner
Sterile disposable plastic 50ml and 10ml tubes.
Hamilton 
HPLC syringes.
Labscan
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Chloroform, Ethanol, Methanol, Propanol.
Medical Supply Company 
Latex exam gloves.
Merck
Acetic acid glacial.
Milipore
Filtering membranes.
Nunc
All tissue culture flasks and plates.
Oxoid
Bacto-tryptone,Bacto-yeast extract, Bacto-agar no.3.
Pharmacia
EAH-Sepharose, QAE sepharose A50.
Phenomenex
HPLC gel filtration column BioSep S3000, 30x0.78., Sample loading 
loops.
Promega
RiboClone cDNA Synthesis System, RiboClone Linker Ligation 
System, Sephacryl S-400 spin columns, Packagene A,gtl 1 Packaging 
system, Taq Polymerase, T4 Ligase and all restriction enzymes with
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corresponding 10X reaction buffers, dNTP's, agarose, E. coli LE392, 
E. coli Y1090.
Reidel-de-Haen
Ammonium persulphate, Bromophenol blue, DMF, Azur-eosin- 
methylene blue (Giemsa stain), EDTA, Glycerol, HC1, Magnesium 
chloride-6-hydrate, KH2PO4, K2HPO4, NaCl, NaOH, NaH2P04, 
Na2HP04, TEMED.
Rhyodyne
HPLC sample loops and injectors.
Schleicher and Schull
Nitrocelulose filter disks 0.45mm, nitrocellulose membranes.
Sigma Chemical Co.
Freund’s complete and incomplete adjuvants, acrylamide, ammonium 
sulphate, bis-acrylamide, BC1P, BSA, gentamycin, heparin, 
hypoxanthine, magnesium sulphate, maltose, NBT, sodium azide, 
sodium citrate, SDS, SDS-PAGE prestained molecular weight markers, 
Tween®-20, alkaline ahosphatase conjugate anti-rabbit IgG, bestatin, 
nitro-bestatin, Leu-AMC, AMC, EDC carbodiimide, X-gal, p- 
nitropheny 1-phosphate tablets.
Sterilin Bibby sterilin 
Sterile disposible plastic pipettes.
Whatman International
CF11 columns, 3 mm blotting paper.
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2.1. Buffers and solutions.
2.1.1. Animal work solutions.
Heparin: 1000 units/ml
Qs to desired volume with sterile water
Giemsa stain.
4 mM Na2HP04 
2.5 mMNaH2P04
10% (v/v) giemsa azur-eosin methylene-blue 
Qs to desired volume with sterile water 
Filter with Whatman paper filters.
2.1.2. Culture media.
2 mM L-glutamine 
20 mg/1 gentamicin
50 mg/1 hypoxanthine or 12.5 mg/1 if ^H-hypoxanthine was to be used 
Qs to desired volume with HI-FCS
2.1.3. ELISA solutions.
Glycine buffer 
0.1 M glycine 
1 mM MgCl2 
1 mM ZnCl2
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Qs to desired volume with deionised water
pH was adjusted to 10.4 with 19 N NaOH and the buffer was filter
sterilised
2.1.4. PAGE solutions.
Bis -acrylamide (30:0.8) Stock solution 
30%(w/v) acrylamide 
0.8% (w/v) N,N-methylene bis-acrylamide 
Qs to desired volume with deionised water 
Filter sterilised and stored a 4°C in a dark bottle.
Non-reducing, non-denaturing sample buffer
0.125 M Tris-HCl pH 6.8
20 %(v/v) glycerol
0.005%(w/v) bromophenol blue
Qs to desired volume with deionised water
filter sterilised and stored at room temperature
10% separating polyacrylamide gel
6.6 ml bis-acrylamide stock
5.0 ml 1.5 M Tris-HCl pH 8.8
8.4 ml deionised water
333 |ll1 10% (w/v) freshly prepared ammonium persulfate (APS)
36.6 Temed
Gel sets in 1-3 hours
12% separating polyacrylamide gel
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8 ml bis acrylamide 
5 ml 1.5 M Tris-HCl pH 8.8 
6.9 ml deionised water
333 p,l 10% (w/v) freshly prepared ammonium persulfate (APS)
36.6 jil Temed
Gel sets in 1-3 hours.
4% Stacking gel 
0.65 ml bis acrylamide stock 
1.25 ml 0.5 M Tris-HCl pH 6.8 
3.1 ml deionised water
250 pi 10% (w/v) freshly prepared ammonium persulfate (APS)
36.6 (0,1 Temed
Gel sets in 1-3 hours
Running buffer for PAGE.
25 mM Tris 
192 mM Glycine 
pH 8.3
Qs to desired volume with deionised water, filter sterilise
2.1.4 (a) SDS-PAGE solutions (prepare native gels but run 
in reducing-denaturing buffersand use denaturing sample 
buffer)
Reducing-denaturing sample buffer 
0.125 M Tris-HCl pH 6.8 
0.1%(w/v) SDS 
3% (v/v) /3-mercaptoethanol
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20%(v/v) glycerol
0.005%(w/v) bromophenol blue
Qs to desired volume with deionised water
filter sterilised and stored at room temperature
Running buffer for SDS-PAGE 
25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS 
pH 8.3
Qs to desired volume with deionised water, filter sterilise
2.1.5. Electroblotting solutions.
Running buffer for SDS-PAGE-electroblotting purposes:
25 mM Tris
192 mM Glycine
0.1% (w/v) SDS
10% (v/v) methanol
pH 8.3.
Qs to desired volume with deionised water, filter sterilise.
Running buffer for PAGE-electroblotting purpose
25 mM Tris
192 mM Glycine
10% (v/v) methanol
pH 8.3.
Qs to desired volume with deionised water, filter sterilise.
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2.1.6. Staining solutions.
Fixing solution:
10% (v/v) methanol,
10% (v/v) acetic acid
Qs to desired volume with deionised water
Commassie stain:
0.1%(w/v) commassie blue R-250
Qs to desired volume with fixing solution
Destaining solution.
30% (v/v) methanol,
10% (v/v) acetic acid
Qs to desired volume in deionised water.
2.1.7. Western Blotting and immunoscreening solutions.
PBS-tween® 0.5 %:.
Tween 0.5% (v/v)
Qs to desired volume with PBS
Blocking solution .
1% (w/v) BSA
Qs to desired volume with PBS
Alkaline phosphatase (AP) buffer 
100 mM Tris-HCl, pH 9.5 
lOOmMNaCl
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5 mM MgCl2
Qs to desired volume with sterile water 
Filter sterilised and stored at room temperature
NBT stock .
75 mg/ml Qs to desired volume with 70% DMF 
Filter sterilised and stored at 4°C in a dark bottle.
BCIP stock.
50 mg/ml
Qs to desired volume with DMF
Filter sterilised and stored at 4°C in a dark bottle.
Alkaline phosphatase development solution
0.66% NBT stock
0.33% BCIP stock
Qs to desired volume with AP buffer
Solution was protected from light and used immediately
2.1.8. PCR programmes.
Standard programme 
stage 1 95°C 5 min
1 cycle
stage 2 95°C 1 min
55°C 2 min 
74°C 2 min
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40 cycles
stage 3 74°C 4 min
1 cycle
Touch down programme 
stage 1 95°C 5 min
1 cycle
stage 2 95°C 1 min
t°C 2 min 
74°C 2 min
5 cycles with t = 65, 63, 61, 57, 55, 50, 48, 46, 44, 42, 40, and 38
stage 3 74°C 4 min
1 cycle
Touch up programme 
stage 1 95°C 5 min
1 cycle
stage 2 95°C 1 min
t°C 2 min 
74°C 2 min
5 cycles with t = 39, 41, 43, 45, 47, 49, 51, 53 , 55 and 57
stage 3 74°C 4 min
1 cycle
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3.0. Methods.
3.1. Maintenance of parasites and preparation of cell free 
extract.
3.1.1. Maintenance of parasites.
P. c. chabaudi AS strain was maintained in CD1 mice as described 
previously (McNally et al., 1992). P. c. chabaudi infected mice were 
adapted to reversed lighting, the artificial daylight beginning at 12 
midnight and ending at 12 noon. The parasitaemia was monitored on 
Giemsa's stained blood smears (see section 3.1.1a.). Parasitised blood 
was drawn from anaesthetized infected mice by cardiac puncture into 
heparinized syringes. Parasites were passaged to non-infected mice or 
used to prepare cell free extract. The passaging was always done with 
ring stage parasites which typically appear in the blood stream between 
7 pm and 8 pm. Cell-free extract was prepared from late trophozoites 
which typically appear in the blood stream between 9 am. and 10 am. 
In collaboration with Angus Bell (Department of Microbiology,
Trinity College Dublin) P. falciparum parasites were maintained in 
human erythrocytes as described previously (Bell et al. 1993) with the 
exception that the culture dishes were incubated in candle jars.
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(a) Giemsa staining.
Infected mice were bled from the tail and blood smears were prepared 
on microscopic slides. The smears was fixed by pouring a few drops of 
methanol on the smears, washed under running sterile water and 
stained by covering the blood smear with giemsa staining solution for 
15 min. The stained slides were washed under running sterile water, 
air dried and observed under a microscope. Parasitised erythrocytes 
were counted and parasitaemia was defined as the percentage of 
parasitised erythrocytes.
3.1.2. Preparation of cell-free extract.
When the P. c. chabaudi parasitaemia reached 15-25% mice were 
anaesthesied, and, blood containing early trophozoites was obtained as 
described in section 3.1.1. The blood was then chromatographed on a 
CF11 column to remove white blood cells and platelets which bind to 
the column. The collected red blood cells were washed in phosphate 
buffered saline (PBS), pH 7.4, the pellet was aliquoted in 500 jol 
fractions and lysed with 500 jj.1 of 0.1%(w/v) saponin for 30 sec on ice 
to obtain free parasites. The free parasites were washed in PBS at 4°C 
to remove haemoglobin by centrifugation (15000 g for 20 min at 4°C). 
This centrifugation step was repeated until the extract was free of 
haemoglobin. Cell-free extracts were then prepared by three cycles of 
freeze-thaw lysis followed by centrifugation (15000 g for 20 min at 
4°C). The cell-free extract containing aminopeptidase activity was 
stored at 4°C and the pellets stored at -20°C.
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3.1.3. Direct fluorogenic substrate analysis in 
polyacrylamide gels.
P. c. chabaudi aminopeptidase activity was located in polyacrylamide 
gels using the fluorogenic peptide substrate L-leucine-amino-methyl- 
coumarin (L-leucine-AMC). Cell-free extracts were prepared as 
described in section 3.1.2. and separated by electrophoresis in non­
denaturing, non-reducing 10% polyacrylamide gels as described 
previously (Laemmli, 1970). Following electrophoresis, the gels were 
washed for 3 x 10 min at room temperature in PBS pH 7.4 each time. 
The gels were then incubated in 50 |iM L-leucine-AMC for 30 min at 
37°C. Fluorescent bands locating the substrate cleaving enzyme within 
the gel were visualised by placing the gel on a UVP chromatove model 
TM-20 UV-Transilluminator and immediately photographed using a 
Polaroid 667 Kodak film.
3.2. In vitro drugs tests.
3.2.1. In vitro culturing of P. c. chabaudi.
P. c. chabaudi infected mice (~10% parasitaemia) were bled when 
parasites had developed to the ring stage (typically 8 pm) or to the 
trophozoite stage (typically 9 am). The cells were washed three times 
in PBS and subjected to chromatography over a CF11 column. The 
parasitised cells collected from the column were then washed in heat 
inactivated foetal calf serum (HI-FCS) which is obtained by placing 
foetal calf serum (FCS) at 55°C for 30 min. The cells were counted in
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a hemocytometer under a microscope and 1x10^ cells were added to 1 
ml of HI-FCS culture media (HI-FCS with 2 mM L-glutamine, 20 mg 
gentamycin/1 and 50 mg/1 or 12.5 mg hypoxanthine/1) containing either
2.5 (iCi/ml 35S-methionine (ring stage parasites) or 1.0 jiCi/ml 3H- 
hypoxanthine (trophozoite stage parasites) in a 24 wells culture plate 
and maintained in a candle jar at 37°C for 16 and 10 hours 
respectively. The cells were removed, and transferred to micro­
centrifuge tubes, washed three times in PBS, lysed in l%(v/v) triton® - 
X 100, homogenised by sonication and protein or DNA-incorporated 
isotopes determined as described previously (O'Donovan et al., 1993).
3.2.2. In vitro culturing of P. falciparum.
P. falciparum parasites were cultured in human erythrocytes as 
described previously (Bell et al., 1993 ). Cultures of 2% haematocrite 
and 0.8% initial parasitaemia were incubated with various 
concentrations of bestatin, nitrobestatin and chloroquine. Parasite 
growth was monitored by measuring lactate dehydrogenase (LDH) 
activity according to the method of Malker (Malker et al., 1993).
3.3. In vivo drugs tests..
3.3.1. Chloroquine
P. c. chabaudi malarial parasites were maintained as described in 
section 3.1.1. CD1 mice were infected with P. c. chabaudi ring stage 
malarial parasites subcutaneously. When the parasitaemia reached 5-
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6%, chloroquine was administered subcutaneously (sc) at 5, 2, or 1 mg 
/ injection / mouse every second day for the first week and every day 
for the following week. Parasitaemia was monitored as described in 
section 3.1.1a.
3.3.2. Bestatin trial 1.
P. c. chabaudi malarial parasites were maintained as described in 
section 3.1.1. CD1 mice were infected with P. c. chabaudi ring stage 
malarial parasites subcutaneously. When the parasitaemia reached 5- 
6%, bestatin was administered subcutaneously (sc) at 5, 2, or 1 mg / 
injection / mouse every second day for the first week and every day for 
the following week. Parasitaemia was monitored as described in section 
3.1.1a.
3.3.3. Bestatin trial 2.
P. c. chabaudi malarial parasites were maintained as described in 
section 3.1.1. CD1 mice were infected with P. c. chabaudi ring stage 
malarial parasites subcutaneously. Bestatin was administered 
subcutaneously (sc) or intravenously (iv) at 2 mg / injection / mouse, at 
the first sight of parasites (< 0.5 % parasitaemia) every day for the 
first week and every second day for the following week. Parasitaemia 
was monitored as described in section 3.1.1a.
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3.4.- Effects of novel bestatin analogues on P. c. chabaudi 
aminopeptidase activity.
In collaboration with Dr. Paul Mc Cormack and Dr. Joshua Howarth 
(School of Chemical Sciences, DCU) bestatin analogues were 
synthesised using modified procedures of Krepski et al., 1986 and 
Duboudin, et al., 1982.
These bestatin analogues were then assayed for their effects on 
aminopeptidase activity. Aminopeptidase was partially purified as 
described in section 3.6.Id. The enzyme assays were carried out by 
incubating the bestatin analogues at various concentrations with the 
purified P. c. chabaudi aminopeptidase for 45 min at room temperature 
prior to adding 50 mM of L-leucine-AMC in a final volume of 1 ml di­
methyl sulphur oxide (DMSO), pH 7.4. The reactions were then 
incubated at 37°C for 30 min and stopped by the addition of 200 |il of 
10% (v/v) acetic acid. Aminopeptidase activity was measured as 
described in section 3.5.1. Bestatin was used as a comparative control 
for aminopeptidase activity inhibition.
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3.5. Inhibition kinetics of P. c. chabaudi aminopeptidase by 
bestatin.
3.5.1. Enzymatic fluorogenic assay for aminopeptidase 
activity.
P. c. chabaudi cell-free extract was assayed for aminopeptidase activity 
using a standard assay as described previously (Curley et al., 1994). 
Aminopeptidase activity was determined by measuring the release of 
amino-methyl-coumarin (AMC) from the synthetic fluorogenic 
substrate, L-leucine-AMC. Enzyme was added to 50 |liM substrate in a 
final volume of 1 ml PBS and incubated 30 min at 37°C. The reaction 
was stopped by addition of 200 |nl of 10% acetic acid. The amount of 
AMC released was determined using a Perkin Elmer luminescence 
spectrometre LS50 fluorimeter (excitation 370 nm, emission 440nm).
3.5.2. Inhibition of P. c. chabaudi aminopeptidase activity, 
by bestatin and nitro-bestatin.
Crude cell-free extracts of P. c. chabaudi aminopeptidase and, was 
incubated with various concentrations of bestatin and nitrobestatin for 
45 min at room temperature prior to adding 50 jiM L-leucine AMC. 
Incubation was continued for 30 min at 37°C and aminopeptidase 
activity was measured as described in section 3.5.1. In collaboration 
with Dr. P. Curley, inhibition of purified P. c. chabaudi 
aminopeptidase by the same aminopeptidase inhibitors was investigated.
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3.5.3. Determination of the inhibitor constants (Ki).
Partially purified or crude cell-free extract of P. c. chabaudi 
aminopeptidase was incubated with a known concentration of bestatin 
in the presence of known concentrations of L-leucine-AMC for 30 min 
at 37°C. This assay was repeated with 2 other concentrations of bestatin 
and aminopeptidase activity was measured as described in section 3.5.1. 
Line Weaver-Burk plots were prepared, one for each concentration of 
inhibitor reaction. The inhibitor constants were determined according 
to the method of Dixon (Dixon et al., 1953).
3.5.4. Time course studies of bestatin inhibition on P. c. 
chabaudi and porcine kidney aminopeptidase activity
Partially purified P. c. chabaudi aminopeptidase and mammalian 
porcine kidney aminopeptidase were pre-incubated with bestatin prior 
to adding 50 fiM L-leucine-AMC. Incubations were stopped at various 
times by the addition of acetic acid and the aminopeptidase activity was 
measured as described in section 3.5.1.
3.5.5. Dissociating rates of bestatin from P. c. chabaudi and 
porcine kidney aminopeptidase.
Partially purified P. c. chabaudi aminopeptidase and porcine kidney 
aminopeptidase were incubated with 2 |iM bestatin for 1 hour at 37°C. 
The mixture was diluted 50-fold (0.04 jxM bestatin) and incubated for 
various time periods prior to the addition of L-leucine-AMC.
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Aminopeptidase activity was measured as described in section 3.5.1 
Partially purified P. c. chabaudi aminopeptidase and porcine kidney 
aminopeptidase were pre-incubated in the same way but without 
bestatin and diluted into PBS containing 0.04 joM bestatin to serve as 
controls.
3.6. Purification and characterization of P. c. chabaudi 
aminopeptidase.
3.6.1. Purification of P. c. chabaudi aminopeptidase.
(a) Affinity chromatography.
The coupling reaction of bestatin to EAH-sepharose 4B and the 
preparation of the affinity column was done as described by the 
manufacturer (Pharmacia affinity chromatography manual). Briefly, 
the swollen gel provided by the manufacturer was washed with 0.5 M 
NaCl. Bestatin was dissolved in sterile water and the pH adjusted to 4.5. 
A slurry was made by mixing 2 volumes of dissolved bestatin with 1 
volume of washed gel at 5 mg bestatin / ml of swollen gel.
Carbodiimide was added in powder form to a final concentration 
of 0.1 M. The suspension was mixed gently and the mixture was 
rotated end-over-end for 4 hours at room temperature. During the first 
hour of coupling the pH was adjusted to pH 4.5. The bestatin/EAH- 
sepharose 4B was washed with a three cycles acid/base wash. Each 
cycle consisted of 0.1 M acetate/ 0.5 M NaCl, pH 4, followed by 0.1 M
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Tris-HCl/ 0.5 M NaCl, pH 8.0. Finally, the coupled slurry was washed 
in sterile water and then with 0.05 M Tris-HCl, pH 8.0.
An affinity column was prepared by pouring the slurry into a 1 
ml syringe carefully avoiding air bubbles. Affinity chromatography 
was performed at 4°C. The affinity column was packed and 
equilibrated by running ten volumes of 0.05 M Tris-HCl, pH 8.0, 
through the column at gravity flow rate or at 0.5 ml / min when a flow 
rate monitor pump was available. At this moment the UV protein 
monitor was set at zero (A280nm= 0.000 units of optical density 
(O.D.)).
Crude P. c. chabaudi cell-extracts (approx. 1 mg/ml protein) 
were prepared as described in section 3.1.2. and dialysed against 0.05 
M Tris-HCl, pH 8.0, or 0.5 ml of concentrated partially purified 
extracts from gel filtration were applied to the affinity column and left 
to incubate for 45 min or recycled three times over the column . One 
ml fractions were then collected until A280nm returned to 0.000 O.D. 
The bound proteins were eluted with a step-wise NaCl gradient (0.1-1 
M) in 0.05 M Tris-HCl, pH 8.0. After all the proteins were eluted, 
(A280 returned to 0.000 O.D. with 1 M NaCl), the affinity column was 
washed with 10 volumes of 0.1 M Tris-HCl, pH 8.0, and then 5 
volumes of 0.05% (w/v) sodium azide. The column was stored in 
0.05% (w/v) sodium azide at 4°C. The collected fractions were assayed 
for aminopeptidase activity (section 3.5.1) and concentrated as 
described in section 3.6.1e
(b) Gel filtration.
Gel filtration was performed by size-exclusion high purification liquid 
chromatography (HPLC). Care was taken to ensure air bubbles were
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not introduced onto the gel filtration column or in the apparatus tubing 
during manipulations. All the buffers for HPLC were sterile filtered 
and degassed before use. All protein samples applied to the gel 
filtration column were sterile filtered.
The HPLC apparatus (Shimadzu LC-9A) was washed in HPLC 
grade methanol until A280 reading (Shimadzu SPD-6AV ) was constant 
(stable baseline on the screen (Axxion chromatography)). The buffer 
was changed to 0.1 M KH2PO4, pH 6.8, until A280 was stable again. 
The gel filtration column (Biosep S3000, 30 x 0.78 cm) was then 
connected to the apparatus and, in order to ensure that the column was 
free of any protein, the column was equilibrated with 0.1 M KH2PO4, 
pH 6.8, overnight at a flow rate of 0.1 ml/min. The following morning 
the flow rate was set at 0.5 ml/min and when the A280 was stable, the 
UV protein monitor was set at zero ( A280 =0.000 O.D.).
A calibration curve of the gel filtration column was obtained 
using proteins of known molecular weight ( IgG, 150,000 BSA, 66,000 
ovalbumin, 45,000 tubulin and P-lactoglobulin, 18,400). Crude P. c. 
chabaudi cell-extracts (approx. 1 mg protein) prepared as described in 
section 3.1.2. and dialysed against 0.1 M KH2PO4, pH 6.8 or 0.5 ml of 
concentrated partially purified extracts from ion-exchange or affinity 
chromatography, were applied to the gel filtration column. 250 j l l I  
fractions were collected until all the proteins were eluted off the 
column i.e. A280 returned to 0.000 O.D. The column was left to run 
for a further 40 min in 0.1 M KH2PO4, pH 6.8, and during this 40 min 
the A280 reading remained at 0.000 O.D. The column was washed in 
0.05% (w/v) sodium azide, disconnected from the apparatus and stored 
in 0.05% (w/v) sodium azide. After disconnecting the gel filtration 
column from the HPLC machine the apparatus tubing was washed with 
HPLC grade methanol and stored in methanol. The collected fractions
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were assayed for aminopeptidase activity and concentrated as described 
in sections 3.5.1. & 3.6.1e.
(c) Ion-exchange chromatography .
QAE-Sepharose which is an anion exchanger was swollen overnight in 
0.1 M Tris-HCl, pH 8.0, at 4°C. The ion-exchange column was 
prepared by pouring 4 ml of the slurry into a 5 ml syringe carefully 
avoiding air bubbles. The ion-exchange column was packed and 
equilibrated by running ten volumes of 0.1 M Tris-HCl, pH 8.0, 
through the column at gravity flow rate or 0.5 ml/min when a flow 
rate monitor pump was available. The UV protein monitor was then set 
at zero (A280nm = 0.00 O.D.)
Crude P. c. chabaudi cell-extracts (approx. 1 mg/ml protein), 
prepared as described in section 3.1.2., were dialysed against 0.1 M 
Tris-HCl (pH 8.0) or 0.5 ml of concentrated partially purified extracts 
from gel filtration were applied and incubated on the ion-exchange 
column for 45 min. One ml fractions were collected until A280nm 
returned to 0.00 O.D. The bound proteins were eluted with a step-wise 
NaCl gradient (0.1-1 M) in 0.1 M Tris-HCl, pH 8.0. During the elution 
process the column shrinks as the concentration of salt increases hence 
the gravity flow rate was maintained constant by moving the buffer 
container upwards away from the column to increase the gravity flow 
rate or downwards closer to the column to decrease the gravity flow- 
rate. (unless a flow rate monitor pump was available). After all the 
proteins were eluted (A280 returned to 0.00 O.D. with 1 M NaCl) the 
ion-exchange column was regenerated and washed with 10 volumes of
0.1 M Tris-HCl, pH 8.0, and then 2 volumes of 0.05% (w/v) sodium
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azide. The column was stored in 0.05% (w/v) sodium azide at 4°C. The 
collected fractions were assayed for aminopeptidase activity and 
concentrated as described in sections 3.5.1 & 3.6.1e.
(d) Preparation of partially purified cell free extract of P. 
c. chabaudi aminopeptidase.
P. c. chabaudi cell-free extracts were prepared as described in section
3.1.2 and assayed for aminopeptidase activity as described in section
3.5.1. The cell-free extract was partially purified to a high degree of 
purification using a combination of size exclusion-HPLC and bestatin 
affinity chromatography as described in sections 3.6.1a & 3.6.1b..
(e) Concentration of collected fractions.
The collected fractions were assayed for aminopeptidase activity as 
described in section 3.5.1. Fractions containing aminopeptidase activity 
were pooled and concentrated with an Amicon 8400 concentrator, 
fitted with an Amicon YM3 membrane (3000 MW cut off), down to
2.0 ml. The concentrator was refilled with either: 0.1 M Tris-HCl, pH
8.0, (when the next purification step was ion-exchange 
chromatography); 0.05 M Tris-HCl, pH 8.0; (when the next 
purification step was affinity chromatography); or 0.1 M KH2PO4, 
(when the next purification step was gel filtration). Concentration was 
continued down to 2.0 ml. This latter process was repeated three times 
to make sure the sample was free of salt and fully equilibrated in Tris 
or Phosphate buffer depending on the following purification step. 
Further concentration (to 500-200 jul) was performed in a Centricon
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and the sample was stored at 4°C. Protein concentration of the samples 
from each purification step was analysed as described in section 3.6.If.
(j) Determination of protein concentration.
Protein concentration was measured in a microtitre plate using the 
BCA standard kit according to the method described by (Redinbaugh, 
et al., 1986). The standard curve was obtained using bovine serum 
albumin (BSA) at 1:4 increasing dilutions, ranging from 2mg/ml down 
to 0.00075 mg/ml. Ten |il of BSA standards and 10-40 fil of the test 
samples whose concentration was sought, were mixed with the BCA 
dye solution provided with the kit. The microtitre plate was incubated 
at 37°C for 1 hour or left at room temperature for 1-3 hours. The 
protein concentration was determined by spectrophotometry at 600 nm. 
A plot of absorbance versus the concentration of BSA standards 
provides a protein concentration standard curve from which the 
concentration of the test samples can be extrapolated.
3.6.2. Characterisation of P. c. chabaudi Aminnopetidase.
(a) Silver nitrate staining.
Gloves were worn at all times especially when handling gels for silver 
staining. Silver nitrate staining was done as described (Sambrook et al. 
1992). The proteins from each purification step were separated by 
electrophoresis on 12% reducing SDS-polyacrylamide gels (Laemli, 
1970). The proteins were fixed by incubating the gel overnight at room 
temperature with gentle shaking in five volumes of fixing solution. The 
fixing solution was discarded and replaced with five volumes of 30%
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methanol and the incubation was continued for 30 min at room 
temperature with gentle shaking. This step was repeated once. The gel 
was washed 3 times in 10 volumes of deionised water for 10 min at 
room temperature with gentle shaking each time. Five volumes of a 
freshly diluted 0.1% silver nitrate (AgN03) solution was added, and 
the gel was incubated for 30 min at room temperature with gentle 
shaking. The gel was washed for 20 sec on each side under a stream of 
running deionised water. Five volumes of a freshly made aqueous 
solution of 2.5% (w/v) sodium carbonate in 0.02% (v/v) formaldehyde 
was added. The gel was incubated at room temperature with gentle 
shaking until stained bands of protein, with an adequate contrast, were 
obtained. The reaction was quenched by washing the gel in 1 % (v/v) 
acetic acid. The gel was stored at room temperature and photographed 
using an image analyser (UVP white/UV Transilluminator and Image 
store 7500).
(b) Production and analysis of polyclonal antisera.
1. Production of polyclonal antisera
P. c. chabaudi aminopeptidase was partially purified by using Ion- 
exchange chromatography and analysed by the direct fluorogenic 
substrate assay as described in section 3 . 6 . 1 . C  and 3 . 1 . 3 .  The 
fluorescent band was cut out of the gels and thinly mashed up. This 
preparation containing approximately 1 5 0  jug of total protein together 
with sonicated Freund’s complete adjuvant (FCA) were used to 
immunise rats for the first immunisation. The same preparation 
together with sonicated Freund's incomplete adjuvant (FIA) were used 
for the following 4 immunisations, four weeks apart. Blood was taken
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from anaesthetised rats by cardiac puncture into non heparinized 
syringes. The blood was left at room temperature to allow it to 
separate into serum and plasma. The serum was collected after 
centrifugation at 2000g for 10 min at room temperature, aliquoted and 
stored at -20°C.
Another immunisation was carried out using partially purified P. 
c. chabaudi aminopeptidase (approx. 150 (ig of total protein) prepared 
as described in section 3.6.Id. In this immunisation rabbits were used 
and unlike the gel slicing method the partially purified sample was 
directly mixed with FCA (v/v) and sonicated, for the first 
immunisation and with FIA for the following four immunisations, four 
weeks apart. Blood was taken from the rabbits (extravenously from the 
vein behind the ear lobe) into non heparinized syringes. Rabbit serum 
was collected and stored as described above.
2. Analysis of polyclonal antisera.
a. Quantitative analysis of serum antibodies.
Quantitative analysis of polyclonal antisera obtained from rabbits and 
rats as described in section 3.6.2b. was performed after every 
immunisation, using the standard enzyme linked immuno-sorbent assay 
(ELISA). The wells of microtitre plates were coated overnight at 37°C 
with 6 jag of P. c. chabaudi aminopeptidase extract from different 
purification steps. The excess binding sites in the wells were blocked 
with 1% (w/v) BSA in 0.5% (v/v) Tween®-PBS (TPBS), washed in 
TPBS, then incubated with various dilutions of polyclonal antisera for 
1 hour at 37°C. The wells were then washed as above and alkaline- 
phosphatase conjugated anti-rabbit or anti-rat IgG added at various
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dilutions for 30 min at room temperature. The plates were washed as 
above and then incubated with a colorigenic substrate /?-nitrophenyl- 
phosphate (pNPP). The quantity of bound serum antibodies present was 
determined by spectrophotometry at 405 nm using a spectrophotometer 
fitted with an ELISA plate reader.
b. Qualitative analysis of polyclonal antisera
Qualitative analysis of serum antibodies obtained from rabbits and mice 
as described in section 3.6.2b. was performed using the standard 
method of Western blotting and Dot blotting. For Western Blotting, 
P.c.chabaudi protein extracts from different purification steps were 
separated electrophoretically in 12% reducing SDS-gel or 10% non 
reducing gels as described (Laemli, 1970). The proteins were 
transferred to a nitrocellulose membrane using a semi-dry 
electroblotter and transfer buffer (see section 2.5) containing methanol. 
The excess sites on the nitrocellulose were blocked with l%(w/v) BSA 
in TPBS. The nitrocellulose was then incubated with various dilutions 
of rabbit serum for 45 min with gentle shaking. After removing the 
primary antibodies, the nitrocellulose membrane was washed 3 x 10 
min in TPBS, then incubated with alkaline phosphatase conjugated anti­
rabbit or anti-rat IgG for 45 min with gentle shaking. The 
nitrocellulose membranes were washed as before and the bound serum 
antibodies were revealed by incubating the membrane with a 
colorigenic substrate solution 5'-bromo-4-chloro-3-indoyl phosphate 
(BCIP). The colour reaction was stopped when the desired background 
was obtained by rinsing the membrane in deionised water several 
times.
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For Dot blotting analysis an aliquot of the sample was deposited 
on a nitrocellulose membrane and left to dry. The membrane was then 
probed as for Western Blotting. The Dot blotting method was ideal for 
analysing denatured and non-denatured samples rapidly at various 
dilutions of serum antibodies.
3.7. Construction of cDNA expression library.
In collaboration with Dr. Paul Curley, a P. c. chabaudi c DNA 
expression library was constructed in the laboratory as described 
(McNally, PhD. thesis, 1994). In brief, the library was constructed as 
described in section 3.7.1-3
3.7.1. Isolation of total RNA and mRNA .
P. c. chabaudi early trophozoites were cultured until parasites 
developed to mature trophozoites (6-8 hours) and harvested as 
described previously (O'Donovan et al. 1993). The pellet was 
resuspended in DEPC-PBS and total RNA isolated using RNAzol 
according to manufacturer's instructions. From total RNA, mRNA was 
isolated using the BRL mRNA isolation system according to 
manufacturer's instructions.
3.7.2 Generation of double stranded cDNA.
The RiboClone® cDNA synthesis kit was used to generate double 
stranded cDNA according to the manufacturers instructions. EcoRl
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linkers were then added to the cDNA in order to ligate into the unique 
EcoRl site of A-gtll arms, this was done using the RiboClone® Linker 
Ligation Kit and Sephacryl® S-400 spin columns. After adding the 
EcoRl linkers the cDNA was ligated and packaged using the 
ProtoClone® and Packagene® systems. A control ligation and 
packaging without a cDNA insert was done in parallel to allow 
determination of the background level religated A,gtl 1 arms. This 
control also provided a supply of wild type A,gtll. The packaged phage 
was then amplified by transfection into LE392 bacteria.
3.7.3. Amplification of phage stock.
The entire packaged phage stock in 100 ju.1 aliquots was used to 
transfect LE392 competent cells. After incubation at 37°C the plates 
were overlaid with 5 ml SM buffer and left at room temperature for 2 
hours with gentle shaking. The SM buffer was then transferred to a 
centrifuge tube and chloroform was added to 5%(v/v) mixed gently, 
and centrifuged at 3000 g for 10 min at 4°C. The supernatant 
containing the amplified phage was removed and chloroform added to 
0.3%(v/v) and stored at 4°C until use. The pellet containing cell debris 
and chloroform was discarded.
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3.8. Preparation of P. c. chabaudi cDNA expression library and 
rabbit antisera for immunoscreening.
3.8.1. Preparation of P. c. chabaudi cDNA expression 
library for immunoscreening
(a) Phage competent bacterial cells.
E. coli LE392 bacterial strain was used to amplify and titrate the 
cDNA expression library. This strain was maintained on Luria Bertani 
(LB) plates. E. coli Y1090 bacterial strain was used to screen the 
cDNA expression library with polyclonal serum antibodies, it was 
maintained on LB plates supplemented with 100 |Lig/ml ampicillin and 
15 (ig/ml tetracycline.
(b) Cloning and preparation of phage competent bacterial 
cells.
All the work involving culture media and cells was carried out in a 
sterile environment, created by working beside a Beck Bunsen burner 
or in a laminar flow. All glassware and pipettes were autoclaved for 20 
min at 105°C and the reagents were either filter sterilised or autoclaved 
for 20 min at 105°C
E. coli LE392 bacterial strain was streaked on LB plates, pH 7.5. 
and incubated at 37°C overnight. One colony from these plates was 
then used to innoculate 5 ml of LB media supplemented with
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0.2%(w/v) maltose, 10 mM MgS04 and cultured overnight at 37°C on 
an orbital shaker. Fifty j l l I  of the freshly grown culture was used to 
innoculate 5 ml of supplemented LB media as above and the culture 
was grown at 37 °C on an orbital shaker until the A600 nm reached 
between 0.6 and 0.9 O.D.
E. coli Y1090 bacterial strain was streaked out on LB plates pH
7.5, supplemented with 100 jig/ml ampicillin and 15 |ig/ml tetracycline 
and incubated at 37°C overnight. A single colony was then used to 
inoculate 5 ml of LB media and grown overnight at 37 °C in an orbital 
shaker.
(c) Transfection of phage competent cells.
For each plate to be poured 100 (ill of the required dilution of phage 
was added to 100 jxl of fresh phage competent cells and incubated at 
37°C for 10 min. This incubation can also be done at room temperature 
for 20 min. During this 10-20 min incubation period 3 ml molten top 
agar supplemented with 10 mM MgS04 was placed at 48°C and LB 
plates prewarmed at 37°C. The transfected cells were then added to the 
molten top agar, gently vortexed and poured onto the prewarmed LB 
plates. The plates were left for 5-8 min to harden. They were then 
covered and incubated upside down, overnight at 37°C.
(d)Titration of phage stock.
One hundred (il of tenfold increasing dilutions of phage stock were 
used to transfect LE392 competent cells as described. The efficiency of 
packaging for both wild type Xgtll and A-gtll containing cDNA insert
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(rXgtll) was determined as the number of plaque forming units (pfu) 
per mg DNA packaged.
3.8.2. Preparation of rabbit antisera for immunoscreening.
(a) Absorption of antisera with E. coli extract and Xg t l l  
wild type.
In order to reduce interference caused by cross reacting IgG 
components and to improve signal-to-noise ratios, the antisera was 
treated with E. coli infected with A,gtll wild type. E. coli Y1090 was 
cultured overnight in 50 ml supplemented LB media as described, 
section 3.7.1b. The culture was centrifuged for 5 min at 2000 g and the 
pellet containing the cells was resuspended in 5 ml PBS. The 
resuspended cells were then sonicated (3 x 20 sec bursts, duty cycle 0.7 
sec). Nitrocellulose filter disks were then saturated with E. coli extract 
by incubating the nitrocellulose filters for 16 hours at 4°C with the 
sonicated solution. The filters were then air dried. The excess binding 
sites on the nitrocellulose filters were blocked by incubating the filters 
for 1 hour at room temperature with 1% (w/v) BSA in TPBS. These 
nitrocellulose filters were then washed 3 x 5  min in TPBS and stored at 
4°C or room temperature until used to preabsorb antisera.
The polyclonal rabbit antisera obtained from rabbits, as 
described in section 3.6.2b, was diluted to 10X the concentration at 
which it would be used for immuno-screening. The diluted antisera was 
then incubated with nitrocellulose filters treated with E. coli extract 
and Xgtll wild type at 4°C overnight. The incubation was then 
transferred to room temperature. The filters were removed, replaced
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with new treated filters and the incubation was continued for onother 6 
hours. This process was repeated twice.
3.8.3. Immunoscreening of P. c. chabaudi cDNA expression 
library.
Immunoscreening of the cDNA expression library was performed 
according to the Promega Protocols and applications guide with some 
modifications. Phage competent E. coli Y1090 was prepared and 
transfected with rA-gtl 1 P. c. chabaudi cDNA expression library and 
A,gtll wild type as described earlier in section 3.7.1c. In order to 
ensure that the full cDNA expression library was plated out, 20 tubes 
containing 100 jil of phage competent E.coli Y1090 were each 
transfected with 100 |il of X diluent containing 2.6 x 10^ pfu cDNA 
library. One extra tube was transfected with Agtl 1 wild type to serve 
as a negative control. The plates were incubated at 42°C for 5 hours 
and then transferred to a 37°C incubator. A nitrocellulose filter disk 
pre-saturated in 10 mM IPTG was gently overlaid on each plate 
avoiding air bubbles. The plates were then incubated at 37°C for 3.5 
hours. The plates were moved to room temperature and the position of 
each filter on the plate was carefully marked with a needle and labelled 
before it was removed. A second filter pre-saturated in 10 mM IPTG 
was then overlaid on each plate after the first one was removed and 
incubated overnight at room temperature.
After the filters were removed from the plates they were rinsed 
in TPBS briefly to remove any residual agar and then incubated 
overnight in l%(w/v)BSA in PBS to saturate nonspecific protein 
binding sites. The filters were then washed 3 x 5  min in TPBS and 
incubated for 45 min with 10 ml primary antibodies (preabsorbed with
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E.coli extract transfected with rX-gtll) at various dilution. The 
primary antibodies were diluted in TPBS. The filters were washed 3 
X10 min in TPBS and then incubated for 30 min with 10 ml of a 
1:7000 dilution of alkaline phosphatase conjugated anti-rabbit IgG. The 
filters were washed in TPBS as described above and blot dried on 
Whatmann Blotting paper, transferred to freshly prepared colorigenic 
substrate solution (BCIP). Clones expressing P. c. chabaudi protein 
reacting to primary antibodies were identified as purple dots. Only the 
clones which appeared purple during the first 3 hours of incubation 
with developing substrate were picked from the corresponding plate. 
These clones were re-screened at 600, 300 and 100 pfu until all the 
colonies from a single clone, tested positive.
(a) Picking positive clones.
The tip of a sterile pipette tip was cut with a sterile scalpel and the cut 
pipette tip was attached to a rubber bulb. This assembly was then used 
to take agar plugs containing the phage colonies of interest. The agar 
plug was incubated in 1 ml of lamda diluent with 0.3% (v/v) 
chloroform and stored this way at 4°C until used for re-screening or 
amplification.
3.8.4. Isolation of rA-gtll DNA.
One hundred pi of a 1:10 dilution of lamda diluent containing phage 
particles was boiled for 10 min to release phage DNA from phage 
capsids. This method yielded enough DNA for PCR analysis using 1-5 
|il of the boiled sample (Sambrook et al., 1989). When more than 500
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ng/ml of DNA was required rXgtl 1 DNA was isolated as described in 
Promega's protocols and applications guide.
3.8.5. Screening of P. c. chabaudi cDNA expression library 
by PCR.
X-gtl 1 recombinant (r^gtll) DNA was isolated from A, phage as 
described earlier. The DNA was then analysed by PCR using universal 
primers LF (5'-GGTGGCGACGACTCCTGGAGCCCG-3') and LR(5’- 
TTG AC ACC AG ACC A ACTGGT A ATG-3'). The standard 
thermocycling programme was used for amplification with the 
universal primers. An internal primer BB10 (5'- 
GGWACWTTRACWGGTGCT-3’) was designed by Dr. J.P. Dalton as 
a consensus sequence of the bestatin binding site of E. coli and Bovine 
lens leucine aminopeptidases. Because this internal primer contains 
wobble sequences, the PCR was performed using various 
concentrations of MgCl2 (0.3-4 mM) and DNA (up to 7 |iil). The 
Touch-up, Touch-down and standard thermocycling programmes were 
used to amplify the DNA preparations.
PCR reaction mix with universal primers LF and LR.
sterile H2O qs to 50 jxl.
PCR reaction buffer 10X 5 ja.1
MgCl2 (50 mM) 1.5 |xl or 3 | u l
dNTPs (1 mM each) 5 jllI
LF (200 ng/ml) 1 J L ll
LR (200 ng/ml) 1 n l
a g t l l  DNAQ0-500 ng/ml) 1-5 1^
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Taq polymerase 0.25 fil
PCR reaction mix with primers LF and BB10
sterile H20 qs to 50 (ill.
PCR reaction buffer 10X 5 |ll
MgCl2 (50 mM) 0.3-4 |iM
dNTPs (1 mM each) 5 JLXl
BB10(200 ng/ml) 1 nl
LF (200 ng/ml) 1 |0,1
r^g tll DNA(10-500 ng/ml) 1-5 (il
Taq polymarase 0.25 nl
PCR reaction mix with primers LR and BB10
sterile H2O qs to 50 jllI.
PCR reaction buffer 10X 5 |ll
MgCl2 (50 mM) 0.3-4 |iM
dNTPs (1 mM each) 5 |xl
BB10(200 ng/ml) 1 (0,1
LR (200 ng/ml) l»il
rA-gtll DNA(10-500 ng/ml) 1-5 |il
Taq polymerase 0.25 \il
The PCR reaction mix was vortexed gently and topped with 50 ml 
mineral oil to avoid evaporation during thermocycling and placed in a 
Hybaid Omnigene thermocycler preheated at 95°C. The Standard, 
Touch-up or Touch-down amplification programme were executed, 
(see appendix).
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3.8.6. Sequencing of amplified PCR fragments.
The PCR reactions products were phenol chloroform extracted. One 
volume of phenol chloroform pH 8.0, was added to 1 volume of PCR 
reaction products, vortexed and centifuged 10 min at room 
temperature. The phenol chloroform phase was removed and the same 
procedure was repeated once. The nucleic acid fractions were 
concentrated by precipitation in 3 volumes 100% ethanol and 1/10 
volumes 3 M NaAc overnight at -20°C followed by two washes in 70% 
ethanol. The pellet was vaccum dried and resuspended in 30 |ol sterile 
TE buffer or water. The fragments were separated electrophoreticaly 
in a 2% TAE agarose gel before being sliced from the gels using a 
separate sterile scalpel for each fragment. The individual DNA 
fragments were eluted from the gel slices by spinning the sliced gels 
through glass beads and subcloned into the PROMEGA pGEM-T® 
vector according to manufacture's instructions. Sunbcloned fragments 
were revealed by digestion of the vector with restriction enzymes Apal 
and Sacl. The vectors containing ligated PCR fragments were sent for 
sequencing to Trinity College Dublin using Ml 3 universal primers and 
an ABI automatic sequencer.
Alternatively the phenol chloroform extracted fragments were 
Gene clean purified (Sambrook et al., 1992) and sent for direct 
sequencing without subcloning, using AF and BB10 primers.
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Chapter 4 
Results
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4.0. P. c. chabaudi AS strain infection.
4.1. P. c. chabaudi AS strain infection in CD1 mice.
P. c. chabaudi AS strain was maintained in male or female CD1 mice. 
This strain undergoes a 24 hour synchronous, intra-erythrocytic 
asexual life cycle, which is biologically adapted to light exposure. In 
order to obtain trophozoites in the morning the mice were maintained 
in reverse light with light exposure beginning at midnight to 12.00 
noon.
4.1.1. Intra-erythrocytic cycle of P. c. chabaudi AS strain.
Early trophozoites can be observed in Giemsa's stained blood smears at 
approximately 7.30 am these develop into mature trophozoites by 
10.30 am and are recognisable by their large vacuoles. Early 
trophozoites can be distinguished from late trophozoites as the former 
do not have large vacuoles and their cytoplasm is not well developed. 
The mature trophozoites begin to devide by schizogony and segmentors 
or schizonts can be seen in Giemsa's stained blood smears by 12.00 
noon and are recognisable by the presence of several nucleii in a single 
parasite. These schizonts are also recognisable by the crystalline 
deposits of hemozoin which appear as small dark granules in the 
parasite vacuoles. By 1.00 pm merozoites formed by schizogony are 
visible in Giemsa's stained blood smears. These merozoites rupture the 
red blood cells causing anaemia and sequester to the endothelial cells. 
During this sequestration period (approx. 3.30-6.30 pm) no parasites
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are visible in Giemsa's stained blood smears. The merozoites re-invade 
the red blood cells to begin a new schizogony cycle, as small rings and 
are visible on Giemsa's stained blood smears at approx. 6.00 pm, by
8.00 pm mature large rings are visible and they continue developing 
into trophozoites through the night.
4.1.2. Symptoms of P. c. chabaudi infection in mice.
P. c. chabaudi AS strain was lethal to male CD1 mice in practically 
100% of the mice infected. Parasitaemia increased in male mice to over 
60%, at this stage several lysed erythrocytes were visible in blood 
smears and the overall number of erythrocytes decreases, free parasites 
were visible as well. The mice trembled with fever, they showed pilo 
erection, depression, closed eye lids, lack of spontaneous movement 
and were very pale and anaemic (blood in urine). These paroxysms 
were regular in P. c. chabaudi infected mice due to the synchronous 
life cycle of the parasite. The fevers and chills are the consequence of 
disrupted erythrocytes and other blood corpuscles due to the liberation 
of successive broods of merozoites. These paroxysms are very 
irregular in P. falciparum infections due to the asynchronous 
development of P. falciparum infections. Death occurred in the next 
12 to 24 hours. This diagnostic and symptomatic study was only done 
once in triplicate, usually the mice were bled before they reached this 
stage.
Female CD1 mice infected with the same strain of rodent malaria 
in the same conditions survived the P. c. chabaudi infection. 
Parasitaemia visibly increased at the same rate as in male mice except 
that when parasitemia exceeded 50-60% the number of parasitised 
erythrocytes begun to decrease and continued to decrease (fig. 11).
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Within the following week all parasitised erythrocytes were cleared 
from the blood stream and the self healed female mice remained very 
healthy for a further 6 months until euthenased.
In over 400 male mice only two male mice survived P. c. 
chabaudi infection. Both these mice had been castrated during a fight 
with other mice.
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Figure 11. Development of P. c. chabaudi infection in CD1 
mice. Mice were infected with ring-stage P. c. chabaudi parasites 
and parasitaemia was monitored daily on Giemsa's stained blood 
smears.
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4.2. Observations on the immunological response to P . c. 
chabaudi infection.
A few days after infection circulating lymphocytes were visible on 
Giemsa's stained blood smears although no parasites were visible yet 
indicating an immunological response to an infection. Most of the 
leukocytes observed at this stage were mononuclear phagocytes 
(monocytes or macrophages) and polymorphonuclear granulocytes 
(neutrophils eosinophils and basophils). On Giemsa's stained blood 
smears all these lymphocytes stained blue with darker shades of blue 
for the nucleus. Monocytes were recognised as having a horseshoe 
shaped nucleus; neutrophils as having multilobed nucleii and 
neutrophilic granules in the cytoplasm. Following this appearance of 
immune cells, parasites became visible in the blood stream 3-4 days 
later. The number of circulating lymphocytes then decreased during 
infection. When the number of parasitised erythrocytes reached 50- 
60% another brusque appearance of circulating lymphocytes became 
visible only in female mice. This second wave of circulating immune 
cells was followed by a decrease in parasitised erythrocytes and the 
immune cells remained visible in great numbers while the number of 
non-parasitised erythrocytes increased. In approximately a week 
following this large increase in circulating lymphocytes no more 
parasitised erythrocytes were visible.
When infected blood from female mice was passaged to male 
mice, for two generations of passages, the treated male mice survived 
the infection in nine out of ten cases (n = 10). When infected blood 
from the same male mice at the third generation was passaged to both
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male and female mice, only the female mice survived the infection. The 
same infected blood was lethal to male mice.
These observations appeared to suggest that survival/death after 
P. c. chabaudi infection was under hormonal control. The female mice 
appear to be able to develop protective immune mechanisms. This self- 
healing behaviour was transferable from female to male mice via 
infected blood from females. Similar observations were made with 
BalbC mice, therefore these results do not appear to be restricted to 
CD1 mice.
4.3. Inhibition of P. c. chabaudi aminopeptidase activity by 
bestatin and nitro-bestatin.
P. c. chabaudi crude cell-free extract aminopeptidase was incubated 
with increasing 1:2 dilution of bestatin and nitro-bestatin ranging from 
1.25-0.0097 jiM for 30 min prior to addition of 20 jiM L-leucine- 
AMC and assayed for aminopeptidase activity. Aminopeptidase activity 
decreased towards an asymptote with increasing concentrations of 
bestatin and nitro-bestatin suggesting that the aminopeptidase was 
inhibited in a Michaelis-Menten manner by bestatin and nitro bestatin. 
Nitro-bestatin was approximately six times more potent an inhibitor of 
P. c. chabaudi aminopeptidase activity than bestatin (fig. 12). Inhibitor 
constants for bestatin and nitro-bestatin (Kp= 0.03 fiM and Ki = 0.0018 
(iM) respectively were determined by the Dixon mathod (figs. 12 B & 
C).
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Figure 12A. Inhibition of P.c.chabaudi crude cell- 
extract aminopeptidase activity by aminopeptidase 
inhibitors bestatin and nitro-bestatin. Crude enzyme 
extract was incubated with various concentrations of 
aminopeptidase inhibitors bestatin or nitro-bestatin for 30 min 
prior to addition of L-leucine-AMC.
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Figure 12B. Determination of the inhibitor constant 
(Ki) for the inhibition of crude cell-free extract of P. 
c. chabaudi aminopeptidase activity by bestatin. Dixon 
plot of the inhibition of crude cell-free extract P. c. chabaudi 
aminopeptidase activity by bestatin in the presence of either 10 
jiM, 20 jiM and 40 jiM of L-leucine-AMC. The intersection of 
the graphs represents Ki = 0.03 |nM on the X axis.
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Figure 12C. Determination of the inhibitor constant 
(Ki) for the inhibition of crude cell-free extract of P.
c. chabaudi aminopeptidase activity by nitro-bestatin.
Dixon plot of the inhibition of crude cell-free extract P. c. 
chabaudi aminopeptidase activity by bestatin in the presence of 
either 20 juM, 30 JJ.M and 40 }iM of L-leucine-AMC. The 
intersection of the graphs represents Ki = 0.0018 j i M  on the X 
axis.
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4.4. Inhibition of P. c. chabaudi and P. falciparum growth in 
vitro by bestatin and nitro-bestatin.
4.4.1. Inhibition of P. c. chabaudi growth in vitro.
The effect of bestatin and nitro-bestatin on the in vitro growth of P. c. 
chabaudi was investigated and compared to that of chloroquine. Ring- 
stage parasites were cultured for 16 hours in the presence of various 
concentrations of inhibitors and 35S-methionine. Both bestatin and 
nitro-bestatin prevented the incorporation of isotope into parasite 
proteins. In these assays the aminopeptidase inhibitors were in the 
order of 2-3 times less effective than chloroquine in inhibiting parasite 
growth (fig. 13.A.).
Assays in which trophozoite-infected erythrocytes were 
incubated in the presence of 3H-hypoxanthine and various 
concentrations of inhibitors showed that both bestatin and nitro-bestatin 
were effective inhibitors of P. c. chabaudi growth of the late stage of 
the asexual cycle of this malaria (fig. 13.B.). Chloroquine is most 
effective against trophozoites, and in our studies had an IC50 of 0.5 
|U.M. Both bestatin and nitro-bestatin were approximately 100-fold less 
effective, having IC50 values of approximately 50|iM. Although the 
inhibitory effect of nitro-bestatin on the malarial aminopeptidase is 20- 
fold more potent than bestatin, there was no significant difference 
between the two reagents' abilities to inhibit P. c. chabaudi growth in 
either assay.
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Figure 13.A. Inhibition of in vitro growth of P. c. 
chabaudi. Purified ring stage infected murine erythrocytes 
(lxl()8) were added to culture medium containing 2.5 |iCi/ml 
35S-methionine and various concentrations of bestatin, nitro- 
bestatin and chloroquine. The amount of protein-incorporated 
radioisotope was estimated 16 hours later. Growth inhibition was 
estimated as the reduction of radioisotope incorporated into 
parasitised erythrocytes incubated in the presence of inhibitor 
relative to parasitised erythrocytes incubated in the absence of 
inhibitor. Non-parasitised murine erythrocytes served as 
background controls.
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Figure 13.B. Inhibition of in vitro growth of P. c. 
chabaudi. Purified trophozoite-infected murine erythrocytes 
(lxl()8) were added to culture medium containing 1.0 jxCi/ml 
3H-hypoxanthine and various concentrations of bestatin, nitro- 
bestatin and chloroquine. The amount of DNA-incorporated 
radioisotope was estimated 10 hours later. Growth inhibition was 
estimated as the reduction of radioisotope incorporated into 
parasitised erythrocytes incubated in the presence of inhibitor 
relative to parasitised erythrocytes incubated in the absence of 
inhibitor. Non-parasitised murine erythrocytes served as 
background controls.
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4.4.2. Inhibition of P . falciparum growth in vitro .
Both bestatin and nitro-bestatin were potent inhibitors of the in 
vitro growth of P. falciparum clone FCH5.C2, with IC50 values of 1.7 
and 0.37 jiM, respectively (fig. 14.A). There was also partial sub-ICso 
inhibition of growth by bestatin such that the potency of the two 
compounds between 0.02-0.1 (iM was equal. In the same assay, the IC50 
for chloroquine was 0.013 jxM.
Inhibition of the growth of K 1/Thailand by bestatin (IC50 = 5 
|liM) and nitro-bestatin (IC50 = 0.82 |iM) was only slightly less than for 
FCH5.C2, inspite of the 10-fold higher IC50 of chloroquine for the 
former (fig. 14.B; IC50 = 0.11 mM). Nitro-bestatin was most potent 
against the early trophozoite stage (17-29 h post-invasion, data not 
shown).
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Figure 14.A. Inhibition of in vitro growth of P. 
falciparum  by aminopeptidase inhibitors and 
chloroquine. P falciparum chloroquine sensitive clone 
FCH5.C2 was tested for it's inhibition by aminopeptidase 
inhibitors and chloroquine. Cultures of 2% haematocrit and 
0.8% initial parasitaemia were incubated in various 
concentrations of bestatin, nitro-bestatin and chloroquine. After 
a 48 h incubation period LDH activity was measured as described 
in section 3.2.2. Growth was expressed as the LDH activity in 
cells incubated in the presence of inhibitor relative to cells 
incubated in the absence of inhibitor.
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Figure 14.B. Inhibition of in vitro growth of P. 
fa lciparum  by aminopeptidase inhibitors and 
chloroquine. P falciparum chloroquine resistant strain 
K 1/Thailand was tested for it's inhibition by aminopeptidase 
inhibitors and chloroquine. Cultures of 2% haematocrit and 
0.8% initial parasitaemia were incubated in various 
concentrations of bestatin, nitro-bestatin and chloroquine. After 
a 48 h incubation period LDH activity was measured as described 
in section 3.2.2. Growth was expressed as the LDH activity in 
cells incubated in the presence of inhibitor relative to cells 
incubated in the absence of inhibitor.
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4 5. In vivo drugs tests.
4.5.1. Effects of chloroquine on P. c. chabaudi infection.
Female and male mice treated with chloroquine at 5% parasitaemia 
showed a distinctive decrease in parasitaemia after 24 hours and in 72 
hours no parasites were visible in the blood stream. When parasitaemia 
was left to increase up to 15% before treatment with chloroquine the 
same results were observed indicating that chloroquine was able to 
clear parasitaemia in 72 hours post administration. The mice treated 
with chloroquine stayed alive and healthy until they were euthenased 
six months later (data not shown).
4.5.2. Effects of bestatin on P. c. chabaudi infection.
(a) Trial i .
Female mice were subcutaneously administered with 5 or 2 mg 
bestatin/ injection/ mouse when parasitaemia reached 5-7% (trial 1) 
Parasitaemia appeared to increase earlier in mice in which bestatin had 
been administered subcutaneously. In addition the peak levels of 
parasitaemia in control mice (approx. 40%) were lower than those 
observed in treated mice. Parasitaemia did not exceed 40% in mice 
treated with 2 mg bestatin/ injection/ mouse but reached 60% in mice 
treated with 5 mg bestatin/injection/ mouse. The control mice appeared 
to clear parasitaemias slower than the treated mice (day 12-22).
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However all mice showed parasite clearance from the blood stream 22 
days post infection (fig. 15).
Male mice showed similar results except that the peak levels of 
parasitaemia in mice treated with 2 mg bestatin/ injection/ mouse were 
lower than the peak levels of parasitaemia in control mice. P. c 
chabaudi infection was lethal to all male mice 15 days post infection 
(fig. 16).
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Figure 15. Drugs trial 1. Summary of the in vivo 
effects of bestatin on parasite growth (female mice).
Mice were infected with ring stage P. c. chabaudi parasites. 
Subcutaneous administration of 5 or 2 mg bestatin/ injection/ 
mouse (PBS for control mice) was initiated when parasitaemia 
reached 5-7%.
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Figure 16. Drugs trial 1. Summary of the in vivo 
effects of bestatin on parasite growth (male mice). Mice 
were infected with ring stage P. c. chabaudi parasites. 
Subcutaneous administration of 5 or 2 mg bestatin/ injection/ 
mouse (PBS for control mice) was initiated when parasitaemia 
reached 5-7%.
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Figure 17. Drugs trial 1. Summary data of the in vivo 
effects of bestatin on parasite growth. Compilation of data 
shown in figures 15 & 16. Mice were infected with ring stage P. 
c. chabaudi parasites. Subcutaneous administration of 5 or 2 mg 
bestatin/ injection/ mouse (PBS for control mice) was initiated 
when parasitaemia reached 5-7%.
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(b) Trial 2.
Female mice were treated subcutaneously (sc), with 2 mg bestatin/ 
injection/ mouse at < 0.5% parasitaemia. Parasitemia in treated mice 
did not exceed 40% although parasites were cleared from the blood 
stream in 15 days after infection as opposed to 22 days in control mice. 
The increase in parasitaemia appeared to be delayed in control mice. 
However when bestatin was administered intravenously (iv) the 
increase in parasitaemia was slightly delayed as opposed to female mice 
in which bestatin had been administered subcutaneously. Distinctively 
parasitaemia did not rise above 20% (fig. 18).
Male mice treated in a similar way died when parasitaemia 
reached > 60%. The increase in parasitaemia was delayed in control 
mice. Also two male mice out of three (one did not survive, data not 
shown) treated intravenously in a similar way reacted as the female 
mice in the sense that they controlled the infection and stayed alive and 
healthy until euthenased 6 months later (fig. 19).
This would suggest that bestatin does have an in vivo antimalarial 
effect on parasite control when administered intravenously. However as 
in the in vitro investigations, in vivo bestatin was not as potent an 
antimalarial as chloroquine.
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Figure 18. Drugs trial 2. Summary data of the in vivo 
effects of bestatin on parasite growth (female mice).
Mice were infected with ring stage P. c. chabaudi parasites. 
Subcutaneous (sc) or intravenous (iv) administration 2 mg 
bestatin/ injection/ mouse (PBS for control mice) was initiated 
when parasitaemia reached < 0.5%.
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Figure 19. Drugs trial 2. Summary data of the in vivo 
effects of bestatin on parasite growth (male mice). Mice 
were infected with ring stage P. c. chabaudi parasites. 
Subcutaneous (sc) or intravenous (iv) administration 2 mg 
bestatin/ injection/ mouse (PBS for control mice) was initiated 
when parasitaemia reached <0.5%.
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Figure 20. Drugs trial 2. Summary data of the in vivo 
effects of bestatin on parasite growth. Compilation of data 
shown in figures 18 & 19. Mice were infected with ring stage P. 
c. chabaudi parasites. Subcutaneous (sc) or intravenous (iv) 
administration of 2 mg bestatin/ injection/ mouse (PBS for 
control mice) was initiated when parasitaemia reached < 0.5 %.
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4.6. Purification and characterisation of P. c. chabaudi 
aminopeptidase.
4.6.1. Purification of aminopeptidase.
Purification of P. c. chabaudi aminopeptidase was first attempted using 
a combination of size-exclusion HPLC and ion-exchange. Crude soluble 
P. c. chabaudi extract was separated on an anion-exchange column 
(QAE-Sepharose) The aminopeptidase activity bound to this column 
was eluted from the column with 0.1 M NaCl (fig. 21 A). This would 
indicate that the P. c. chabaudi aminopeptidase has a moderate negative 
charge.
After this purification step an increase in total aminopeptidase 
activity was observed (yield 155%) and a purification, factor of 3.9 
was obtained (Table 1.). The sample (1.1) was analysed by direct 
fluorogenic analysis in a 10% non-reducing, non-denaturing 
polyacrylamide gel. In this gel the proteins are electrophoretically 
separated according to their overall electrical charge, molecular weight 
size and conformation. A fluorescent band localising aminopeptidase 
activity was observed (fig. 23; lane 3). Sample 1.1 was subsequently 
subjected to size-exclusion HPLC. The proteins resolved in one sharp 
peak and the aminopeptidase activity eluted as a symmetrical peak at 
approximately 60-70 kDa (Sample IH.2, fig. 21B). The overall 
purification factor was approximately 124 fold (Table 1). Forty to fifty 
percent of initial activity was lost during these two purification steps.
When the purification was performed in the reverse order i.e., 
by size-exclusion HPLC followed by ion-exchange chromatography, an
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increase in total aminopeptidase activity was observed after the size- 
exclusion step indicating the presence of an aminopeptidase inhibitor in 
the crude cell-free extract (corroborating observations made by ion- 
exchange and HPLC purifications ). Greater aminopeptidase activity 
was observed in diluted crude cell-free extract than the undiluted crude 
cell-free extract emphasising the presence of an endogenous 
aminopeptidase inhibitor. A similar overall purification factor was 
obtained.
Another strategy to purify the aminopeptidase to a high degree 
of purification was performed by exploiting the biological properties 
of this aminopeptidase to bind specifically and non-covalently to 
bestatin by affinity chromatography. Crude cell-free extract separated 
on a size-exclusion HPLC column resolves as two broad protein peaks. 
The aminopeptidase activity eluted as a symmetrical peak at 80 kDa 
(Sample (H.l) in the first of the protein peaks (fig 22A). A purification 
factor of 5-6 fold was obtained at this step (Table 2). In addition, an 
increase of total aminopeptidase activity was observed (yield 225%) 
again confirming the presence of an aminopeptidase inhibitor in the 
crude extracts. Sample H.l was applied to the bestatin affinity column. 
The aminopeptidase binds to the bestatin-affinity column and is eluted 
with 0.2-0.3 M NaCl (sample HB.l, fig.22B). This step increased the 
purification factor by approximately 15-fold providing an overall 
purification factor of > 100 fold (Table 2).
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Figure 21A. Purification of P. c. chabaudi 
aminopeptidase. Crude cell-free extract of aminopeptidase 
(approx. 1 mg), was separated on an anion-exchange 
chromatography column equilibrated in 0.1 M Tris-HCl, pH 8.0. 
Bound aminopeptidase activity eluted with 0.1M NaCl using a 
step-wise gradient and was detected using the fluorogenic 
substrate L-leucine -AMC.
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Figure 21B. Purification of P. c. chabaudi 
aminopeptidase. Crude cell-free extract of aminopeptidase 
(approx. 1 mg), was separated on an anion-exchange 
chromatography column, followed by a size-exclusion HPLC gel 
filtration column equilibrated in 0.1 M KH2PO4, pH 6.8. 
Aminopeptidase activity was detected using the fluorogenic 
substrate L-leucine -AMC.
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Figure 22. Purification of P. c. chabaudi
aminopeptidase. (A) Crude cell extract of P. c. chabaudi was 
separated on a HPLC gel filtration column equilibrated in 0.1 M 
KH2PO4, pH 6.8. Eluted protein was measured by absorbance at 
280 (Q) nm and aminopeptidase activity was detected using the 
fluorogenic substrate L-leucine-AMC (♦). (B) Aminopeptidase 
activity eluted from the gel filtration column (sample H.l) was 
pooled and applied to a bestatin EAH-Sepharose 4B affinity 
column equilibrated in 0.05M Tris-HCl, pH 8.0. Bound 
aminopeptidase activity was eluted between 0.2-0.3 M NaCl 
using a step-wise gradient. Inset: 12 % SDS-PAGE analysis of 
crude cell-free extract (lane 1) and purified fraction HB (lane 2)
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Figure 23. Direct fluorogenic substrate analysis of 
aminopeptidase activity in polyacrylamide gels. (A)
Crude cell-free of aminopeptidase was purified by a combination 
of ion-exchange and size-exclusion HPLC. Fractions from each 
purification step were analysed on a non-denaturing, non­
reducing 10% polyacrylamide gel. Lane 1: crude extract, lane 2: 
fraction IH.l., from ion-exchange chromatography followed by 
size-exclusion HPLC, and lane 3: fraction I.I., from ion- 
exchange chromatography.(B) Crude cell-free extract of 
aminopeptidase was purified by a combination of size-exclusion 
HPLC gel filtration and bestatin-EAH-Sepharose 4B affinity 
chromatography. Fractions from each purification step were 
analysed on a non-denaturing, non-reducing 10% polyacrylamide 
gel. Lane 1: crude extract, lane 2: fraction H.I., from size- 
exclusion HPLC gel filtration, and lane 3: fraction HB.l., from 
size-exclusion HPLC gel filtration followed by bestatin-affinity 
chromatography.
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Table 1. Purification table of P. c. chabaudi aminopeptidase. Crude cell-free extract of 
P. c. chabaudi aminopeptidase (100 |il) was purified by a combination of anion-exchange 
chromatography and size-exclusion HPLC gel fitration.
Step Protein
(mg)
Total
activity
(units)
Specific
activity
(Units/mg)
Yield
(%)
Purification
factor
Crude extract
\
0.106 0.312 2.95 1
Ion-exchange 0.040 0.48 12 153.8 3.9
Size-exclusion
HPLC
0.0009 0.33 366.66 105.8 124.3
Table 2. Purification table of P. c. chabaudi aminopeptidase. Crude cell-free extract of 
P. c. chabaudi aminopeptidase (600 (J.1) was purified by a combination of size-exclusion-HPLC 
gelfiltration and bestatin-affinity chromatography.
Step Protein
(mg)
Total
activity
(units)
Specific
activity
(Units/mg)
Yield
(%)
Purification
factor
crude extract 0.6 3.2 5.3 1
size-exclusion
HPLC
0.234 7.2 30.7 225 5.79
Bestatin-affinity
chromatography
0.0097 5.2 536 162 101.13
4.6 2. Characterisation, of purified P. c. chabaudi 
aminopeptidase.
(a) SDS-PAGE analysis
One hundred ng of concentrated samples from each purification step 
was mixed with reducing and denaturing sample buffer (see section 
2.1.4a). SDS is an ionic detergent which denatures the proteins by 
breaking all non covalent bonds thus unfolding the proteins, in doing 
so, SDS also provides a uniformed negative charge to the denatured 
proteins this ensures that all the proteins will migrate in the same 
direction when submitted to an electric field, (3-mercaptoethanol is a 
reducing agent which reduces RS-SR covalent bonds to 2RSH thus 
further unfolding the proteins, should there be any covalent disulphide 
bridges. When submitted to electrophoresis the proteins migrate and 
are separated solely according to their molecular weight. The samples 
including prestained molecular weight markers were then boiled for 2 
min to dissolve any aggregated proteins. The samples were loaded on a 
12% gel and submitted to an electric field using SDS-PAGE running 
buffer (see section 2.1.4a) at 30 mA.
Silver staining of these gels revealed a concentration of bands in 
the region of 60-70 kDa compared to the crude extract. Sample HB was 
very interesting as one of the bands at approximately 63 k Da has the 
same intensity as the co-migrating band in the crude extract ( fig 22, 
inset., lane 2).
127
(b) Direct fuorogenic localisation of aminopeptidase activity 
in polyacrylamide gels.
The pooled samples from each purification step were submitted to non­
reducing and non-denaturing PAGE on a 10% gel (native gels) using 
PAGE running buffer (section 2.1.4) at 30 mA. In this type of gels the 
proteins migrate and are separated according to their overall electrical 
charge , molecular weight and conformation when submitted to an 
electric field. These gels were analysed by direct fluorogenic 
localisation . Samples H.l., 1.1 and HB.l., revealed intense fluorescent 
bands thus localising the presence of aminopeptidase activity in native 
gels (fig. 23 A & B lanes 1 & 3). Samples H.l and IH.l revealed very 
weak bands.
(c) Quantitative analysis of polyclonal antisera.
Antiserum was obtained from immunised rabbits as described (see 
section 3.6.2b). 500 ng of samples H.l and HB.l., and the crude cell 
extract of aminopeptidases were coated onto ELISA plates and analysed 
with 1:100 and 1:1000 increasing dilutions up to 1:10.000 of rabbit 
anti- sera. /?-nitrophenyl phosphate was used as a substrate for alkaline 
phosphatase. When pNpp is hydrolysed by the alkaline phosphatase the 
soluble end product is yellow in colour. The intensity of the yellow 
colour is directly proportional to the amount of antibodies bound to the 
coated protein extracts This amount of bound antibodies was 
determined by spectrophotometry at 405 nm. The quantity of 
antibodies bound were inversely proportional to the anti-sera dilutions 
between 1:100 and 1:4000. Beyond this value the readings were very
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fluctuant and would indicate non specific or background readings. 
Sample HB.l showed the highest values of bound antibodies. Indicating 
that the anti-sera was reacting specifically to the sample against which 
it was produced (fig. 24). These results were used to determine the best 
dilutions to use in any further work which necessitated the use of this 
antisera. ELISA analysis of rat antisera showed similar results (data not 
shown)
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Figure 24. Quantitative analysis of rabbit anti-sera 
raised against purified P. c. chabaudi aminopeptidase. 
ELISA analysis of Rabbit anti-sera. Rabbits were immunised 
with sample HB.l. Bound antibodies were detected with the 
colorigenic substrate p-Nitro phenyl phosphate at 405 nm.
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(d) Qualitative analysis of polyclonal antisera.
The quality of the polyclonal antisera was analysed by Western 
blotting. The pooled fractions from each purification step were 
concentrated and freeze dried before resuspension in 50 Jil PBS. 10 jul 
of each sample were subsequently submitted to reducing-SDS-PAGE or 
non-reducing PAGE. The gels were transfered to nitrocellulose filters 
which were probed with 1:50, 1:100 and 1:500 dilutions of rat anti­
sera raised against sample IH.l., or rabbit anti-sera raised against 
fractions HB.l.,. Samples I.I., IH.l., and crude extract probed with rat 
anti-sera revealed four distinctive protein bands with molecular 
weights in the region of 60-70 kDa (fig. 25). The samples H.I., HB.l., 
and crude extract probed with rabbit anti-sera revealed a smear in the 
same region (fig. 26 A.). Probing of non-reduced, non-denatured 
samples H.I., HB.l., with rabbit anti-sera revealed a smear with the 
crude extract only (fig. 26 B.) no protein bands were detected with 
native samples probed with rat anti-sera.
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Figure 25. Qualitative analysis of polyclonal rat anti­
sera. Samples from each purification step were submitted to 
reducing SDS-PAGE and transferred to nitrocellulose filters. 
The filters containing crude cell extract (lane 1), fraction IH.l., 
(lane 2) and fraction I.I., (lane 3) were probed with rat anti­
sera raised against P. c. chabaudi aminopeptidase, fraction IH.l.
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Figure 26. Qualitative analysis of polyclonal rabbit 
anti-sera. Samples from each purification step were submitted 
to (A) reducing SDS-PAGE and transferred to nitrocellulose 
filters. The filters containing crude cell extract (lane 1), fraction 
H.I., (lane 2) and fraction HB.l., (lane 3) were probed with 
rabbit anti-sera raised against P. c. chabaudi aminopeptidase 
fraction HB.l. (B) The samples were submitted to non­
denaturing, non-reducing PAGE before being transferred to 
nitrocellulose filters . Lane 1, contains crude cell extract, 
lane 2, fraction H.l and lane 3. fraction HB.l.
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4.7. Enzyme kinetics and inhibition studies of the purified P. c. 
chabaudi aminopeptidase.
4.7.1. Effect of substrate concentration on the rate of the 
aminopeptidase catalysed reaction.
The effect of the concentration of L-leucine-AMC on the rate of the 
aminopeptidase catalysed reaction was investigated. Plots of enzyme 
activity ( v o )  versus substrate concentration showed that at a low 
substrate concentration, the initial reaction velocity, vo, was nearly 
proportional to the substrate concentration, and the reaction was thus 
approximately first order with respect to the substrate. However, as the 
substrate concentration was increased, the initial rate increased less, so 
that it was no longer nearly proportional to the substrate concentration; 
in this zone, the reaction was mixed order. As the concentration was 
further increased, the reaction rate became essentially independent of 
substrate concentration and asymptotically approached a constant rate. 
In this range of substrate concentration the reaction was essentially 
zero order therefore the enzyme was saturated with respect to the 
substrate. These observations are in accordance with simple Michaelis- 
Menten kinetics (data not shown). The Michaelis-Menten theory 
assumes that this reaction is reversible and that the enzyme first 
combines with the substrate to form the enzyme-substrate complex ES; 
the latter then breaks down in a second step to form free enzyme and 
the product. Based on this theory we can therefore write-
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[ E ]  +  [ S ]  * = <  [ E S ]  * = 3  [E ] +  [ P 1 
k-i k-2
With [E] = Aminopeptidase concentration 
[S] = L-leucine-AMC concentration
[ES] = Aminopeptidase:L-leucine-AMC complex concentration 
[P] = (AMC + L-leucine) concentration
We can also write the Michaelis-Menten equation (Briggs & Halden) 
v0=Vmax [S] /KM+[S].
Where vo is defined as the initial reaction velocity, Vmax as the 
maximum initial reaction velocity, [S] as the concentration of substrate 
and Km as the Michaelis-Menten constant the substrate concentration at 
which the initial reaction velocity is half maximal.
This equation can be transformed into the Lineweaver -Burk equation
1/vo = KM/Vmax X.1/[S] + 1/Vmax
Plots of 1/vo versus 1/[S] determined that Km = 20 mM and Vmax =
5.6 mmol AMC released/min/mg protein for the P. c. chabaudi 
aminopeptidase with respect to L-leucine-AMC
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4 7.2. Inhibition kinetics of malaria aminopeptidase by 
bestatin.
Purified aminopeptidase was pre-incubated with various concentrations 
of bestatin or nitro-bestatin for 45 min at room temperature prior to 
adding the substrate and measuring aminopeptidase activity. Plots of 
activity versus the concentration of bestatin or nitrobestatin showed a 
decreasing hyperbole which asymptotically approaches a constant rate. 
This would suggest that bestatin and nitro-bestatin inhibit 
aminopeptidase activity in a Michaelis-Menten manner.
Lineweaver-Burk plots of 1/vo versus 1/[S] for each inhibitor 
concentration revealed a family of straight lines intersecting at a 
common intercept on the 1/vo axis (fig 27.A). This graph is 
characteristic of competitive inhibition (Lehninger, 1978). The 
presence of bestatin increased the apparent Km of the aminopeptidase 
for L-leucine-AMC, but did not affect the Vmax. We can therefore 
assume that bestatin and nitrobestatin can combine with the free 
aminopeptidase in such a way that it competes with L-leucine-AMC for 
binding at the active site. This theory also assumes that a competitive 
inhibitor binds reversibly with the enzyme to form an enzyme- 
inhibitor complex [El] analogous to the enzyme-substrate complex. The 
inhibitor molecule is not chemically changed by the enzyme.
The reversibility of inhibition of the aminopeptidase by bestatin 
was confirmed as the malarial aminopeptidase incubated with 2 |xM of 
bestatin regained total activity upon a 50 fold dilution (fig. 28.B). This 
concentration of bestatin inhibits the enzyme more than 95%. This 
reactivation occurred immediately, and no difference in activity was
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observed between samples assayed at time 0 and after 3 hours, 
indicating that bestatin dissociates rapidly from the malarial enzyme.
Based on the Michaelis-Menten formalism we can write:
[E] + [I] —  IEI1k-i
k  I E ) l l )
k,=T E ir
[I]= bestatin concentration
[EI]=bestatin:aminopetidase complex concentration
The inhibitor constant Ki can be defined as the dissociation constant of 
the enzyme-inhibitor complex:
From the plots of 1/vo versus 1/[S] we know that the slope of the 
uninhibited reaction is KM/Vmax and the slope for the inhibited 
reaction is KM/Vmax(l+ [I]/Ki). The inhibiting constant Ki can be 
calculated from this relation however, using the method of Dixon 
which consists of plotting 1/vo versus [I] (Dixon, M. et al., 1953), 
values for the inhibitor constants were determined for bestatin (fig
27.B; Ki = 50.7nM) and nitro-bestatin (Ki = 2.51 nM). These constants 
are similar to those reported for the "slow-binding, tight-binding" 
bestatin-like inhibitors of a variety of mammalian and plant 
aminopeptidases (Taylor, 1993).
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Figure 27. Determination of the inhibitor constant (Ki) 
of purified P. c. chabaudi aminopeptidase by bestatin.
(A) Lineweaver-Burk plot of activity (arbitrary units) of P. c. 
chabaudi aminopeptidase incubated with varying concentrations 
of L-leucine-AMC in the presence of 0 jiM (■), 0.1 jxM (•) and 
0.3 |iM bestatin (A ) .  (B) Dixon plot of the inhibition of P. c. 
chabaudi aminopeptidase by bestatin. The enzyme was incubated 
with varying concentrations of bestatin, in the presence of either 
15 JiM (■) and 60 p,M (•) L-leucine-AMC.
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4.7.3. Comparison of malarial aminopeptidase with porcine 
kidney aminopeptidase.
In contrast to the time-dependent inhibition observed for porcine 
kidney aminopeptidase, the plot of activity versus time reveals that the 
binding of bestatin to the malarial aminopeptidase is rapid (fig. 28.A). 
When the reversibility of bestatin inhibition was investigated the 
malarial aminopeptidase regained total activity upon dilution (fig.
28.B). This reactivation occurred immediately, and no difference in 
activity was observed between samples assayed at time 0 and after 3 
hours, indicating that bestatin dissociates rapidly from the malarial 
enzyme. In contrast similar experiments with the porcine kidney 
aminopeptidase reveal that its activity increases with the length of the 
post-incubation period (fig 28.B).
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Figure 28. Inhibition kinetics of aminopeptidase by 
bestatin. (A) P. c. chabaudi (■) and porcine kidney 
aminopeptidases (•) were incubated with 50 |iM L-leucine-AMC 
in the presence of 0.5 (0,M and 2.0 |iM bestatin, respectively. 
Control reaction with no inhibitor for P. c .chabaudi (□) and 
porcine aminopeptidase (o) are also shown. (B) P. c. chabaudi (■) 
and porcine kidney aminopeptidases (•) were incubated for 1 
hour with 2 jiM bestatin, diluted 50-fold and incubated for 
various time periods prior to addition of L-leucine-AMC. The 
measured activities are given as a percentage of the activities 
determined for the enzymes incubated in the absence of 
inhibitor.
4.8.1. Structure and nomenclature of synthesised bestatin 
analogues.
1 .A. 1,5-diphenyl-4-amino-3-hydroxy-pent-1 -ene.
2.B. Ar-Benzoyl-l,4-diphenyl-4-amino-3-hydroxy-but-l-ene 
3 .C. 1 -phenyl-3-hydroxy-4-amino-but-l -ene
4.D. l,4-diphenyl-4-amino-3-hydroxy-but-l-ene
5.E. 4-phenyl-4-amino-3-hydroxy-but-l-ene
6.F. 6-phenyl-5-amino-4-hydroxy-hex-2-ene
7.G. 5-amino-4-hydroxy-hex-2-ene
8.H. 5-phenyl-5-amino-4-hydroxy-pent-2-ene
9. [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine or 
Bestatin
4.8. Effects of novel bestatin analogues on P. c. chabaudi
aminopeptidase activity.
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OH
A. 1,5-diphenyM-amino-3-hydroxy-pent- 1-ene c e
B. iV-benzoyl-1,4-di-phenyl-4-amino-3-hydroxy-but-1 -ene
NH2
CM
C. l-phenyl-3-hydroxy-4-amino-but- 1-ene
OH
D. 1,4-diphenyl-4-ainino-3-hydroxy-but-1 -ene
F. 6-phenyl-5-amino-4-hydroxy-hex-2-ene
H 3C
NH2
C H
G. 5-amino-4-hydroxy-hex-2-ene
H. 5-phenyl-5-amino-4-hydroxy-pent-2-ene
H3'
h 3c
,  V o  X J
CH
[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoy]-L-leucine or Bestatin
4-phenyl-4-amino-3-hydroxy-but-1 -ene
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Most of these compounds were insoluble in PBS but they were all 
soluble in DMSO. A control assay was performed with aminopeptidase 
in PBS and DMSO, pH 7.4 without bestatin and in the presence of 
bestatin. Comparison of aminopeptidase activity in DMSO and PBS ( 
with and without bestatin) showed that DMSO did not affect 
aminopeptidase activity in any way. All the activity assays were 
therefore performed in DMSO, pH 7.4. Each set of compounds 
consisted of a mixture of the four isomers of the molecule. Activity 
assays were performed three times in duplicate with molecules A-C. 
The results obtained with compounds A-C can therefore be considered 
reproducible, however activity assays with compounds D-H were only 
performed once in duplicate. It can therefore be justifiably argued that 
the results obtained with compounds D-H are not necessarily 
reproducible as they are. For this reason the discussion on this section 
will be mostly based on compounds A-C although the other molecules 
will also be referred to.
At concentrations of 2-10 |xM bestatin analogues D, A, B and C 
inhibited aminopeptidase activity, with compound D showing the 
highest level of inhibition, (fig. 29; Table 3). Compounds E, G and F 
enhanced aminopeptidase activity (fig. 30; Table 3). at higher 
concentrations (10-100 |uM) of bestatin analogous compounds, only 
compounds A, B and C continued to inhibit aminopeptidase activity 
(fig. 29; Table 4), compounds D and F on the other hand enhanced 
aminopeptidase activity at these concentrations. Compounds E, G and H 
continued to enhance aminopeptidase activity, (fig. 30; Table 4).
4.8.2. Effects of novel bestatin analogues on aminopeptidase
activity
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Molecules D and F behave like "allosteric effectors" of aminopeptidase 
activity (fig. 31).
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Drugs concentration (jiM)
Figure 29. Effects of bestatin analogues on P. c. 
chabaudi aminopeptidase activity. Inhibition of 
aminopeptidase activity by synthetic bestatin analogous 
compound. P. c. chabaudi purified aminopeptidase was incubated 
with various concentrations of bestatin analogues. 
Aminopeptidase activity was detected using the fluorogenic 
substrate L-leucine-AMC.
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Drugs concentration (|uM)
Figure 30. Effects of bestatin analogues on P. c. 
chabaudi aminopeptidase activity. Activation of 
aminopeptidase activity by synthetic bestatin analogous 
compound. P. c. chabaudi purified aminopeptidase was incubated 
with various concentrations of bestatin analogues. 
Aminopeptidase activity was detected using the fluorogenic 
substrate L-leucine-AMC.
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Figure 31. Effects of bestatin analogues on P. c. 
chabaudi aminopeptidase activity. Note-these analogues 
inhibit aminopeptidase activity at low concentrations but enhance 
aminopeptidase activity at higher concentrations.
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Table 3. Inhibition and activation of aminopeptidase activity by
bestatin and bestatin analogues at 2-10 (iM
Compounds Residual
activity (%)
Inhibition
(%)
Activation
(% )
Bestatin -96 196
Molecule D 14.6 85.4
Molecule A 60 40
Molecule B 64 36
Molecule C. 74 26
Molecule F 76 24
Molecule E 200 100
Molecule G 366 266
Molecule H 808 708
Residual activity when aminopeptidase was preincubated with 2-10 pM 
bestatin and bestatin analogous molecules.
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Table 4. Inhibition and activation of aminopeptidase activity by
bestatin and bestatin analogues at 10-100 |xM.
Compounds Residual
activity (%)
Inhibition
(%)
Activation
(% )
Bestatin -96 196
Molecule A. 38 62
Molecule B. 56 44
Molecule C. 68 32
Molecule D. 616 516
Molecule E. 1452 1352
Molecule F. 1660 1560
Molecule G. >2000 >1900
Molecule H. >2000 >1900
Residual activity when aminopeptidase was preincubated with 10-100 
(iM bestatin bestatin and bestatin analogous molecules
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4.9. Cloning of P. c. chabaudi aminopeptidase.
4.9.1. Immunoscreening of P. c. chabaudi cDNA expression 
library.
The titre of the library was calculated as 2.95 x 1 C)6 pfu/ml for library 
A and 3.68 x 10^ pfu/ml for library B
Twenty plates with ~ 2000 pfu were used in the primary 
screening with 1/100 and 1/1000 dilutions of preabsorbed anti P. c. 
chabaudi aminopeptidase extract. After four rounds of primary 
screening from each library a total of seven clones expressed proteins 
specific to the antisera (primary positive clones). These clones were 
picked and left to diffuse in X diluent buffer for secondary screening in 
order to increase the immunoscreening specificity.
4.9.2. PCR screening of P. c. chabaudi cDNA expression 
library
(a) Primers.
The internal primer BB10 (5'-GGWACWTTRACWGGTGCT-3') was 
designed as a consensus sequence from the bestatin binding site of E. 
coli and Bovine lens leucine aminopeptidases. LF (5'- 
GGTGGCGACGACTCCTGGAGCCCG-3 ) and LR (5’- 
TTGACACCAGACCAACTGGTAATG-3') are universal 1 primers 
situated on either side of the unique Xgtll EcoRl cloning site .The
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annealing temperature for the universal primers is 45°C-55°C. 
However the annealing temperature for the internal primer is 40°C- 
60°C due to the presence of the wobble sequences.
(b) Amplification of DNA fragments by PCR.
Attempts to amplify DNA fragments directly from the cDNA library 
DNA preparations, using BB10 and AF or A,R primers produced 
amplified fragments in the region of 70 bp. This fragment was 
obtained only when large quantities of DNA preparations were used (3- 
6 (Ltl). When smaller quantities were used no amplification was 
observed. However a DNA preparation from which fragments of 500 
and 200 bp had been amplified were supplied by Dr. P. Curley.
In order to minimise non-specific binding of this primer the 
PCRs were performed with various concentrations of MgCl2. 
Amplification of the DNA preparations with 1.5, 3 mM MgCl2 and 
Touch up or Touch down thermocycling programmes, revealed the 
presence of 5 fluorescent bands of 1000 bp, 500bp, 450bp 200bp, and 
170 bp (fig. 32 A & B). BB10 and LF primers were used for this 
amplification. At different concentrations of magnesium different size 
fragments were amplified- The bands obtained with 1.5 mM MgCl2 
were of very weak intensity for the larger fragments and the fragment 
of 1000 bp is not visible or absent. PCR performed with 3 mM MgCl2 
however revealed high intensity fragments regardless of the size.
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Figure 32. Screening of P. c. chabaudi expression library by 
PCR. (A) PCR was performed in the presence of 1.5 mM (lanes 2-11) 
and 3 mM (lane 12 & 13) MgCl2 and various increasing amounts of 
template DNA using touch up thermocycling. Lane 1 is a negative 
control without template DNA. (B) Fragments were amplified by PCR 
in the presence of 1.5 mM MgCl2 by touch up (lane 7) and touch down 
(lanes 2-5) thermocycling. Lanes 1 & 8 are negative controls without 
template DNA.
152
(c) Sequencing of amplified DNA fragments.
The amplified DNA fragments were sequenced as described in section
3.8.6 and the Blast Network Service was used to screen the gene bank 
for homologous sequences. The most homologous proteins and nucleic 
acid sequences retrieved from the Blast service were E. coli proteins or 
Lambda cloning. The presence of Lambda homologous sequences 
suggests that the amplified fragments were from E. coli competent cells 
used to amplify the cDNA library, or contamination.
In light of these results the Gene bank was screened for leucine 
aminopeptidases. These aminopeptidases were aligned in order to detect 
a consensus aminoacid and nucleotide sequence. Indeed the metal ion 
(Burley et al., 1992; Wood et al., 1993) binding site turns out to be 
quite conserved and a consensus nucleotide and aminoacid sequence was 
revealed (see appendix).
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Region 1.
R. prowazekii 5'GTT.GGT.AAA.GGA.GTT.ATT.TTT.GAC 
L. esculentum 5’GTT.GGA.AAG.GGA.TTA.ACT.TTT.GAC 
Cattle kidney 5'GTT.GGG.AAG.GGG.ATT.ACC.TTT.GAC 
A. thaliana 5'GTT.GGA.AAA.GGA.TTG.ACG.TTT.GAC 
S. tuberosum- 5'GTT.GGA.AAG.GGA.TTA.ACT.TTT.GAC 
Consensus- 5'GTT.GGa. AAg. GGA. tTw. ACt.TTT. GAC
R. prowazekii V G K G V I F D-
L. esculentum V G K G L T F D-
Cattle kidney V G K G I T F D
A. thaliana V G K G L T F D
S. tuberosum V G K G L T F D
E. coli V G K G L T F D
Bovine lens V G K G I T F D-
P. crispum V G K G L T F D
C. elegans V G K G L T F D
Potential primers from region 1
Nan.l-(5'GTT GGA AAG GGA TTT ACT TTT GAC-3’) Most 
conserved nucleotide sequence
Nan la (5'GTT GGA AAG GGA TTA ACT TTT GAC-3’)
Nan lb-(5’GTT GGA AAG GGA TTG ACT TTT GAC-3’)
The Tm for the most conserved nucleotide sequence is 66°C ± 10°C. 
These aminoacids in bold have been shown to be involved in metal 
interaction when bestatin is bound to Bovine lens leucine 
aminopeptidase (Burley et al., 1992)
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Region 2.
R. prowazekii- 5'AAT.ACC.GAT.GCT.GAA.GGT.CGT.TTA 
L. esculentum- 5'AAC.ACG.GAT.GCT.GAG.GGT.AGA.CTC 
Cattle kidney- 5'AAC.ACC.GAT.GCT.GAG.GGG.AGA.CTT 
A. thaliana-— 5’AAC.ACA.GAT.GCT.GAA.GGT.CGT.CTA 
S. tuberosum- 5'AAT.ACT.GAT.GCT.GAG.GGT.AGG.CTC 
Consensus- 5'AAc. ACc. GAT.GCT.GAg. GGT.aGw. CTm
R. prowazekii N T D A E G R L
L. esculentum N T D A E G R L
Cattle kidney N T D A E G R L
A. thaliana N T D A E G R L
S. tuberosum N T D A E G R L
E. coli N T D A E G R L
Bovine lens N T D A E G R L
P. crispum N T D A E G R L
C. elegans N T D A E G R L
primers region 2
Nan.2-(5'AAC ACC GAT GCT GAG GGT-3') most conserved 
nucleotide sequence.
Nan 2a-(5'AAC ACC GAT GCT GAA GGT-3’)
The Tm for the most conserved nucleotide sequence is 56°C ± 10°C. 
These aminoacids in bold have been shown to be involved in metal 
interaction when bestatin is bound to Bovine lens leucine 
aminopeptidase (Burley et al., 1992)
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Region 3.
R. prowazekii—GCC.ACT.CTA.ACA.GGA.GCA-3' 
L. esculentum—GCA.ACA.TTA.ACT.GGT.GCT-3' 
Cattle kidney— GCC.ACC.CTG.ACA.GGT.GCC-3'
A. thaliana GCT.ACT.TTG.ACC.GGG.GCC-3’
S. tuberosum— -GCA.ACA. TTA.ACT.GGT.GCT-3' 
Consensus GCm.ACm.tTa. ACm. GGt.GCm-3'
R.prowazekii -— A T L T G A
L. esculentum — A T L T G A
Cattle kidney -----A T L T G A
A. thaliana —- —A T L T G A
S. tuberosum — A T L T G A
E. coli .......... —A T L T G A
Bovine lens —■—A T L T G A
P. crispum —-■—A T L T G A
C. elegans — —A T L T G A
Primer region 3
5'GC(A/C) AC(A/T) TTA AC(A/T) GGT GC(C/T) which is infact 
BB10. designed from this region contains mostly C, A or T for every 
3' position of the aminoacids. This region is less ideal for primer 
design than regions 1 and 2
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Chapter 5 
Discussion
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5.1. Plasmodium chabaudi chabaudi in CD1 and Balb/C mice
5.1.1. P. c. chabaudi infection in mice.
P. c. chabaudi AS strain was lethal to male CD1 and Balb/c mice 
whereas female CD1 and Balb/c mice infected with the same strain of 
rodent malaria in the same conditions survived P. c. chabaudi infection 
(fig. 11, section 4.1.2). These observations suggest that survival/death 
after P. c. chabaudi infection is under hormonal control regardless of 
the strain of infected mice. The female mice are able to develop 
protective immune mechanisms. The hypothesis that the survival/death 
after P. c. chabaudi infection was under hormonal control and 
independent of the strain of mice used was similar to studies carried 
out by Wunderlich and co-workers (Wunderlich et al., 1988). Their 
studies suggest that this self-healing capacity of female mice against P. 
c. chabaudi AS strain infection is due to the low circulating levels of 
circulating testosterone. Male mice can exert the same self-healing 
behaviour after castration. The protective mechanisms exherted by 
female mice towards P. c. chabaudi are not only under the control of 
testerone but other gonadal factors are thought to be implicated 
(Schmitt et al., 1990). These protective mechanisms are mediated by 
splenic non-T cells involving secreting B-cells (Wunderlich et al., 
1988). Susceptible mice also show deficiency in oxygen metabolism and 
la expression which may contribute to the suceptibility of these hosts to 
this intraerythrocytic parasites (Stevenson et al., 1992)
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Innate resistance to P. falciparum has only been observed in 
individuals possesing genetically modified haemoglobin, deficiency in 
G-6-PD (Friedmann et al., 1979; Nagel, 1990; Beutler, 1994), and, 
individuals who belong to the Duffy negative blood group type (Boyd 
& Stratman-Thomas).
5.1.2. Observations on the immunological response to P. c. 
chabaudi infection.
A few days after infection circulating immune cells were visible on 
Giemsa's stained blood smears from both male and female mice, 
although no parasitised erythrocytes were visible, indicating an 
immunological response to an infection as most of the immune cells 
observed at this stage are known to be phagocytes and antigen 
presenting cells when stimulated by lymphokines. This first 
immunological response observed a few days after infection could be 
explained by the inflammatory system being triggered by the 
inoculation of parasites.
The number of circulating immune cells (phagocytes) decreased 
as parasitised erythrocytes begun to appear in the circulation in both 
male and female mice, indicating an immuno-supression reaction. This 
first immunological response is not sufficient to block parasite 
devellopement in the host as parasitaemia continued. A second wave of 
circulating phagocytes appear only in female mice when parasitaemia 
aproached lethal doses indicating immuno-stimulation. This second 
wave of immuno-stimulation must be specific to the parasitised 
erythrocytes as within a week of this reaction there is total clearance of 
parasitised erythrocytes from the blood stream. The lysed erythrocytes 
are simultaneously replaced by new red blood cells indicating
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activation of hemopoiesis. In male mice parasitaemia augemented until 
death occured without any detactable rise in circulating immune cells 
nor stimulation of hemopoiesis.
5.1.3. Transfer of protective immune cells.
Adoptive transfer experiments showed that male mice were able to 
control P. c. chabaudi infection when the infections were performed 
with infected blood from female mice. This indicates that protective 
immune cells are transferable from female to male mice. These 
protective immune cells maintain their protective capacities when 
transfered to male mice which do not have the natural capacity to 
induce protective immunity against P. c. chabaudi.
5.2. Anti-malarial effects of aminopeptidase inhibitors bestatin 
and nitro-bestatin.
5.2.1. Inhibition of P. c. chabaudi and P. falciparum growth 
in vitro by bestatin and nitro-bestatin.
Bestatin and nitro-bestatin both exhibited anti-malarial effects when 
they were added at various concentrations to P. c. chabaudi and P. 
falciparum cultures although they were not as efficient as chloroquine 
(fig. 13 A & B; section 4.4.1). The implication is that these reagents 
inhibit growth by blocking malarial aminopeptidase activity, although 
it is possible that they may interfere with other enzymes. The 
aminopeptidase inhibitors could inhibit growth of P. c. chabaudi
160
cultures initiated at ring or trophozoites stages. In addition the 
aminopeptidase inhibitors were most effective against the early 
trophozoite stage of P. falciparum. These inhibitors appear to have a 
greater anti-malarial effect on the trophozoites. The very stage when 
most cell metabolism such as haemoglobine degradation, nucleic 
division, and protein synthesis is taking place (slomianny et al., 1983, 
Goldberg et al., 1991; fig. 13 B; section 4.4.1).
The IC50 obtained for bestatin (1.7 |iM) and nitro-bestatin (0.37 
|llM) in the assay revealed that in comparison to chloroquine these 
inhibitors were 131 to 28-fold less effective, respectively. However the 
aminopeptidase inhibitors were equally effective against a chloroquine 
sensitive clone FCH5.C2 and resistant strain Kl/Thailand (fig. 14 
A&B, section 4.4.2). It is important to note that the Ki values for 
bestatin and nitro-bestatin were in the order of 30-fold to 150-fold less 
than their respective IC50 values, which may indicate that these polar 
molecules do not readily penetrate the erythrocyte membrane and 
probably the parasite plasma membranes.
Aminopeptidase from P. c .chabaudi has been localised in the 
cytoplasm, associated to ribosomes where it is synthesised and then 
migrates to associate to pynocytotic vesicles as soon as these are formed 
(Slomianny et al., 1983) These vesicles empty their contents into the 
food vacuole where haemoglobin degradation is initiated (Goldberg et 
al., 1991). The existence of a transport system for haemoglobin 
derived peptides to be vehicled outside the acid food vacuole is a 
possibility These observations indicate that bestatin and nitro-bestatin 
could block aminopeptidase activity either in the cytoplasm where it's 
optimal activity can be exherted, or/and in the pinocytotic vesicles 
where maximal activity can not be exherted due to the acidic pH of 
these vesicles. However enzymes have been reported to be localised and
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be physiologically active in cellular environments that did not 
correspond to their in vitro determined pH optimum. Either way these 
reagents need to cross the erythrocyte, parasite and/or pinocytotic 
vesicles and digestive vacuole membranes before reaching their site of 
action.
It follows, therefore, that modifications of these molecules to 
make them more hydrophobic, lipophilic and osmiophilic may increase 
their anti-malarial activity as such analogues would cross membrane 
barriers with greater ease regardless of the localisation of the 
aminopeptidase. The hydrophobicity of the molecule should be such 
that the molecule is still soluble in physiological and intracellular 
fluids. The modifications should preferably improve malarial 
aminopeptidase inhibition while diminishing mammalian 
aminopeptidase interaction.
5.2.3. Effects of bestatin on P. c. chabaudi in vivo.
(a) Subcutaneous administration of bestatin to P. c. chabaudi 
infection in mice.
Plots of parasitaemia versus days post infection indicated a delay in 
increase of parasitaemia in both male and female mice treated 
subcutaneously with bestatin (fig, 15, section 4.5.2). The higher level 
of parasitaemia in treated female mice compared to female control 
mice, suggests an antagonistic effect of bestatin on the female mice's 
ability to control parasitaemia. The amount of bestatin administered 
and the frequency of administration does not appear to modify these 
observations. Subcutaneous administration of 2 mg or 5 mg of bestatin 
does not improve the overall health of the mice even when the
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frequency of admistration was modified inspite of the delay in 
infection.
This lack of therapeutic effects could be due to 1) The dosage 
used in these studies was not sufficient to induce therapy. Bestatin being 
a peptidomimetic is prone to proteolysis by endogenous proteases hence 
short bioavailability. These reason imply that bestatin would have a 
high renal clearance rate. Increasing the dosage and the frequency of 
administration would increase the plasma concentration of bestatin in 
the renal artery hence decreasing the renal clearance of bestatin and 
bioavailability. 2) Bestatin circulation may be limited by it's polarity 
when admistered subcutaneously. Intravenous admistration would 
deliver the drug closer to it's target. At the same dosage bestatin could 
show therapeutic effects as expected from the in vitro studies. 3) A 
combination of hypothesis 1 and 2, i.e., increase the dosage and 
frequency of admistration. Administer the drug closer to it's target 
therefore intravenously. I decided to maintain the dosage and 
frequency but administer the drug intravenously.
(b) Intravenous administration of bestatin to P. c. chabaudi 
infected mice.
When bestatin was administered intravenously at the same dosage. A 
small delay in infection was observed confirming that the delay 
observed in s.c treated mice was indeed engendered by the 
aminopeptidase inhibitor bestatin. Parasitaemia did not exceed 20% in 
self-healing treated female mice as opposed to 60% (fig. 18-20) when 
bestatin was administered s.c., indicating a possible increase in 
bioavailabilty, Most striking was the results obtained with i.v treated 
male mice, parasitaemia did not exceed 25% unlike the male control
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mice and the s.c treated male mice, these male mice were able to 
control P. c. chabaudi infection just like the female mice. These were 
healthy non-castrated male mice.
(c) Bestatin as an immuno-modulator and a biological 
modifier.
In both i.v treated female and male mice a decrease in parasitaemia was 
evident on Giemsa's stained slides and parasitaemia did not exceed 
25%. Intravenous administration of bestatin also appeared to induce 
self-healing in male mice. This would suggest that bestatin treatment 
helps male mice to override the immunosuppressive effects engendered 
by the high ciculating levels of testosterone or/and other gonadal 
factor(s). However, bestatin is not as effective as chloroquine in vivo . 
Chloroquine treatment clearered P. c. chabaudi infected erythocytes 
from the blood stream in 72 hours when administered subcutaneously. 
Bestatin was only effective as an anti-malarial within the dosage range 
used in these studies, when administered i.v. This would support the 
suggestion that the antimalarial effects of bestatin are limited by the 
dificulty encountered by this compound when crossing membrane 
barriers . No toxicity was observed with bestatin whether bestatin was 
administered subcutaneously or intravenously.
The dosage used in these in vivo trials would suggest that the 
therapeutic effect exherted by (iv) bestatin treatment would be more 
likely due to the immunomodulatory effects of bestatin which do not 
require high doses of bestatin rather than a direct antimalarial activity 
of bestatin. This suggestion would explain the observed diminution of 
parasitaemia accompanied by a large increase in circulating immune 
cells when parasitaemia reached approx. 15% in intravenously treated
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male mice. Although the same phenomenon of a sudden apparition of 
lymphocytes is visible in un treated self-healing female mice and is 
immediately followed by a decrease in parasitaemia. This same 
phenomenon of a sudden invasion of circulating lymphocytes is not 
observed in control male mice to whom P. c. chabaudi infection is 
lethal. Therefore male mice would be better models for an intensive 
bestatin trial for in vivo anti-malarial effects. First, because they are 
incapable of self-healing this malaria unlike female mice, therefore any 
diminution in parasitaemia will be the consequence of bestatin 
treatment. Second, although there is a slight apparition of lymphocytes 
a few days after infection no immune cells increase is observed on 
Giemsa's stained smears when parasitaemia reaches near the lethal dose 
of parasitised erythrocytes in control male mice. Therefore any sudden 
outburst of circulating lymphocytes observed after treatment can be 
attributed to bestatin treatment as this was indeed the case with male 
mice after intravenous administration of bestatin.
These in vivo bestatin trials have shown the immunomodulatory 
effects of bestatin and chloroquine. Macrophage cytotoxicity was 
observed as parasites were cleared from the male mice who received 
intravenous administration of bestatin. The same results were obtained 
with subcutaneous administration of chloroquine in 72 hours. This 
would indicate that the half life time of chloroquine is far greater than 
that of bestatin and that chloroquine has a much easier access to it's site 
of action than bestatin. Host aminopeptidases may also have been 
affected by the bestatin treatment. A good antimalarial should be able 
to target parasite enzymes easily with minimal effect on host enzymes.
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5.2.4 Effect of some bestatin analogues on aminopeptidase
activity.
Nitro-bestatin is a commercial synthetic analogue of bestatin. These 
two molecules differ by a single addition of a nitro group on 
parabenzyl of bestatin. This single addition increases the inhibiting 
activity of nitro-bestatin by at least five times (fig. 9, Nishizawa et al., 
1977) showing that a single chemical modification of natural 
aminopeptidase inhibitors such as bestatin and amastatin can affect 
aminopeptidase activity and hence anti-malarial activity.
There are three functional groups in bestatin, COOH, NH2, OH 
and the phenyl group for steric purposes. The carboxyl group was 
eliminated from all the analogues.
h3c
H-iCX
H OH 
Nitro-bestatinBestatin
166
The bestatin analogues synthesised and assayed for 
aminopeptidase activity showed that although the leucine moiety of 
bestatin was important for aminopeptidase activity inhibition, 
aminopeptidase inhibition was still possible (fig. 29, section 4.8.2). In 
comparison to bestatin, the lower levels of inhibition could be 
attributed to the elimination of the COOH group in all the analogues 
analysed. Modification of the amino group by addition of N-Boc also 
lowered the level of inhibition (Compound B, section 4.8.1). The best 
level of inhibition was obtained with compound A, 1,5-di-phenyl-4 - 
amino-3-hydroxy-pent-l-ene in which these functional groups were 
maintained with the exception of the carboxyl group. However 
Compound D showed the highest levels of inhibition at lower 
concentration (fig. 31). Substitution of the phenyl group by a less bulky 
alkyl group showed activation of aminopeptidase activity (fig. 30 
section). This indicates that the steric effects of the phenyl group are 
implicated in aminopeptidase inhibition and so is the carboxylic group 
(Nishizawa et al., 1977, Taylor et al, 1993). Substitution of the Leucine 
in bestatin by methyl showed a dramatic increase in aminopeptidase 
activity (Compound H). This increase in aminopeptidase activity is still 
an unclear phenomenon frequently observed with some bestatin 
analogues (Taylor et al., 1993). All these molecules are in actual fact 
analogues of 3-amino-2 hydroxy-4-phenyl-butanoic acid (AHPBA)
The concentration of the compounds also appeared to modify the 
direction of aminopeptidase activity. Two of the compounds 
investigated for aminopeptidase activity appeared to have allosteric 
effects on the aminopeptidase (fig. 31, section 4.8.2). At low 
concentrations they behaved as inhibitors whereas at high 
concentrations they behaved as activators (Tables 3 & 4).
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The results observed can be biased in the sense that the activity 
assays were carried out with a mixture of the four isomers of each 
compound. These activity assays should be repeated with the single 
isomers of each compound. In addition to the polar functional groups 
the design of bestatin analogues will have to include biosteric 
requirements to improve aminopeptidase inhibition.
However some inhibitors with low Ki constants on 
aminopeptidases are strong anti-malarial. Chloroquine showed a Ki = 
0.41 mM (Vander jagt et al., 1989) It would be of great scientific and 
therapeutic interest to investigate the anti-malarial effects of these 
bestatin analogues.
5.3. Purification and characterization of P. c. chabaudi 
aminopeptidase.
5.3.1. Purification of aminopeptidase from P.c.chabaudi 
cell-free extracts.
The P. c. chabaudi aminopeptidase interacted with the anion exchange 
column QAE-Sepharose equilibrated in 0.1 M Tris-HCl, pH 8.0. This 
interaction would suggest that this P. c. chabaudi aminopeptidase is 
negatively charged at pH 8.0. This observation is in agreement with the 
pi detected in P.c.chabaudi extracts described by charet et al., (1980). 
Indeed four pis were described of 5,85 to 5,5 (Table 5) indicating that 
at pH 8.0 the aminopeptidase would be charged negatively. The bound 
fraction containing aminopeptidase activity was eluted with a low ionic
168
strength of sodium chloride (0.1 M NaCl) suggesting that this P. c 
.chabaudi aminopeptidase is only slightly negatively charged at pH 8.0.
Whether the first purification step was ion-exchange , size- 
exclusion or affinity chromatography an increase in aminopeptidase 
activity was observed. This increase in activity after every first 
purification step could indicate the presence of an endogenous 
reversible aminopeptidase inhibitor in the crude extract. These 
purification steps were performed in non-reducing conditions. 
Therefore the endogenous aminopeptidase inhibitor would not be 
bound to the aminopeptidase via disulphide bonding. A reversible 
inhibitor that combines directly to the enzyme can be removed by 
dialysis or simple dilution to restore full enzymatic activity. This was 
verified by diluting the crude cell-free extract and comparing the 
activity with the same volume of undiluted crude cell-free extract. 
These observations are in agreement with an association-dissociation 
equilibrium between the enzyme and the inhibitor, where by the 
dissociation constant is increased upon dilution and during purification. 
Therefore in the crude extract only part of the enzymatic activity of 
the aminopeptidase is measured. During the first step of purification 
the endogenous aminopeptidase inhibitor dissociates from the 
aminopeptidase thus revealing the full enzymatic activity of the 
aminopeptidase. However this inhibitor would not be present at a 
saturating concentration to totally inhibit the aminopeptidase in the 
crude cell-free extract.
Reducing SDS-PAGE analysis followed by silver staining 
revealed the presence of several bands with prominent bands in the 
region of 60-70 k Da. This analysis appears to suggest that 1) Other 
proteins other than the aminopeptidase bind to the bestatin affinity 
column. No other proteins other than aminopeptidases have been
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purified using bestatin affinity columns as one of the purification steps 
in my knowledge. In addition no aminopeptidase has been purified in 
one step by using bestatin affinity columns (Masatoshi et al., 1994 
Inversen et al., 1992). 2) The presence of more than one 
aminopeptidase. The suggestion of four different aminopeptidases in P. 
c. chabaudi with the same apparent molecular mass has previously been 
reported (Charet et al., 1980). Western blot analysis using polyclonal 
antisera raised against the ion-exchange purified aminopeptidase (fig.,
25, section 4.6.2) revealed four bands in the region of 60-70 k Da. 
Charet and co. workers describe P. c. chabaudi aminopeptidase activity 
detected by non reducing gel filtration at approximately 90,000 Da. 
However analysis on an electrofocalising column, revealed four 
different pis (5.85, 5.7, 5.6, 5.5) indicating a possibility of four 
different aminopeptidases with a very close apparent molecular weight 
of 90,000 Da (Charet et al 1980). This molecular weight is also 
consistent with the 80 ± 10 kDa determined by non-reducing HPLC for 
the P. c. chabaudi aminopeptidase by Curley et al (1994). 3). That the 
aminopeptidase is not a monomeric enzyme. All the proteins revealed 
by western blot analysis with both antisera (section 4.6.2) appear to 
suggest that the aminopeptidase(s) is/are (a) monomeric enzyme(s) as 
no bands are detected below or above the 60-90 kDa region (fig. 25 &
26, section 4.6.2). Direct substrate analysis also localises all 
aminopeptidase activity in the same region (fig. 23A, section 4.6.1)
SDS-PAGE analysis of the bestatin affinity purified 
aminopeptidase shows that a band with the same intensity as the co- 
migrating band in the crude extract is more prominent than the other 
bands in the same region. This prominent band is situated at 
approximately 63 kDa (fig. 22B, section 4.6.1). Western blot analysis 
using polyclonal antisera raised with this same fraction reveals a smear
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band in the same region (fig. 26, section 4.6.2). The appearance of a 
smear rather than distinct bands also indicates the presence of more 
than one protein interacting with the polyclonal antibodies. Although 
these aminopeptidases have been classified as leucine aminopeptidases 
highest enzymatic activity was observed with alanyl- substrates (Charet 
et a l, 1980; Vander jagt et al., 1984). In cannot be excluded that the 
four aminopeptidases could be a mixture of leucine and alanine 
aminopeptidases which are genetically different (Sanderink et al.,
1988) thus different epitopes could be produced and recognised by 
different antibodies. However alanine aminopeptidases are generally 
membrane bound (Sanderink et a l, 1988) whereas all these 
aminopeptidases were cytosolic. To date no plasmodial aminopeptidase 
sequence is available. A summary of aminopeptidases from P. c. 
chabaudi and P. falciparum is presented in tables 5 & 6.
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Table 5. Aminopeptidases from rodent malaria.
Author Source App. mw. pH Pi Temp. Inhibiting Activating Effect of antimalarials
(kDa.) optimum optimum
(°Q
ions ions
Charet et al., 1980 P. c. chabaudi 90 7.2 5.85
5.7
5.6
5.5
52 Co2+
Zn2+
Ca2+
Mn2+
Ca2+
Mg2+
Chloroquine ++++ 
Quinacrine + 
Primaquine ++ 
Quinine
Gyang e ta l., 1982 P. yoelii nigeriensi s90 7.2 5.3 42 ±H g2+  
±Z n2+ 
± Mn2+
Ca2+
Mg2+
Curley et al., 1994 P. c. chabaudi
\
80 ± 1 0 7.2 ND 50 Mn2+
Hg2+
Cd2+
±Z n2+
Curley et al., 1994 P. berghei 80 ± 1 0 7.2 ND 42 Mn2+
Hg2+
Cd2+
±  Zn2+
Ca2+.
Mg2+
Mn2+
This work P. c. chabaudi 63±10 ND Chloroquine ++++ 
Nitro-bestatin +++ 
Bestatin ++
App. mw. (apparent molecular weight); Temp (temperature).
Table 6 . Aminopeptidases from human malaria.
Author Source App.mw. Pi PH Temp. Inhibiting Act. Effect of antimalarials
(kDa.) opt. opt.
(°Q
ions ions
Gyang etal., 1982 P. falciparum 186 6.05 7.5 Hg2+,
Zn2+,
Cd2+
Ca2+ Amodiaquin
Chloroquine
Primaquine
++++
+++
Vander jagt etal., 1984 P. falciparum 100 6.8 7.2 Hg2+,
Zn2+
Chloroquine
Mefloquine
Quinacrine
Quinine
++++
++
+
P. falciparum 
Chloroquine S (HB3) 
Chloroquine R (NCI)
Primaquine -
vander jagt etal., 1987
63
63
7.5
7.5
Chloroquine ++++
Curley et al., 1994 P. falciparum > 80 N.D 7.2 50-55 Mn2+,
Hg2+,
Cd2+
This work Chloroquine
Nitro-bestatin
Bestatin
++++
+++
++
App. mw (apparent molecular weight); opt. (optimum); Temp (temperature); Act. (activating) S. chloroquine (sensitive), R. (resistant)
The kinetic studies of this aminopeptidase show that the malarial 
aminopeptidase extracted from P .c. chabaudi parasites as described 
earlier is a metallo-aminopeptidase although the metal co-factor has not 
yet been determined, moderately thermophilic with a temperature 
optimum of 35-45°C and has a near neutral pH optimum of 7.2 (Curley 
et al., 1994). The malarial aminopeptidase showed simple Michaelis- 
Menten kinetics with respect to the substrate L-leucine-AMC, 
Lineweaver-burk plots were used to determine a Km = 20 jiM and a 
Vmax=5.6 |J,M AMC released/ml/min/mg protein (fig. 27B, section
4.7.2). The stoichiometry of the catalysed reaction has not yet been 
determined experimentally. These results confirm the results obtained 
with crude cell extract P. c. chabaudi aminopeptidase (section 4.3).
5.4.1. Inhibition kinetics of P. c. chabaudi aminopeptidase 
by bestatin and nitro-bestatin.
The natural aminopeptidase inhibitor bestatin (Umezawa et al., 
1976) and it's derivative nitro-bestatin were both potent competitive 
inhibitors of the purified aminopeptidase. Dixon plots were used to 
determine a Ki = 50.7 nM for bestatin and Ki = 2.51 nM for nitro­
bestatin. Nitro-bestatin was 5-10 times more potent an inhibitor than 
bestatin.
5.4. Kinetic characterization of purified P. c. chabaudi
aminopeptidase.
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The binding of bestatin to purified malarial aminopeptidase and 
porcine kidney aminopeptidase was shown to be fully reversible. 
However, the binding and dissociation of bestatin to the purified 
malarial aminopeptidase appeared to be rapid as the malarial 
aminopeptidase regained activity immediately upon dilution and the 
degree of inhibition was totally independent of the time of incubation, 
in accordance (fig. 28, section 4.7.3) with the Michaelis-Menten 
theory. This observation would exclude bestatin from the "slow- 
binding, tight-binding inhibitors" category in which bestatin is 
suggested to belong. In contrast, the binding and dissociation of bestatin 
to porcine kidney aminopeptidase is time-dependent as the degree of 
inhibition appears to increase with time (fig. 28, section 4.7.3.). This 
time-dependence is superficially similar to that observed with an 
enzyme undergoing irreversible inhibition. The same superficial 
similarity to irreversible inhibition was observed with other plant and 
mammalian aminopeptidases (Wilkes et al, 1985, Burley et a l, 1991). 
However the inhibition of porcine kidney and other plant and 
mammalian aminopeptidases by bestatin has been shown to be fully but 
slowly reversible by greatly diluting the enzyme:inhibitor complex, 
and then incubating for periods of 3-48 hours prior to assay (Wilkes et 
a l, 1985). This observation would maintain bestatin in the "slow- 
binding, tight binding inhibitor" category. These molecules usually 
resemble the transition state for the substrate-bound enzyme (Burley et 
a l, 1991) which accounts both for their very low inhibitor constants 
(Ki for bestatin is typically in the range of lO'^-lO'^M) and their slow 
binding/dissociation kinetics (Wilkes et al, 1985).
This difference in binding and dissociation of bestatin to malarial 
and mammalian aminopeptidases could indicate that the bestatin binding
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site of this malarial aminopeptidase differs from that of the mammalian 
aminopeptidases.
5.5. Cloning of P. c. chabaudi aminopeptidase.
Screening of P. c. chabaudi cDNA expression library.
The amplification was performed on cDNA templates which are 
complementary to the mRNA transcripts. The non specificity of the 
amplified DNA fragments can be explained by the presence of wobble 
sequences in the internal primer BB10. The use of touch up and touch 
down thermocycling increases non-specific annealing of the primers 
The wobble sequences in the primers also indicate that the region of the 
bestatin binding site from which this primer was designed is not a very 
"conserved" region in terms of the nucleotide sequence. When 
thermocycling is performed by the touch up or touch down 
programme the annealing temperature is gradually increased or 
decreased. At some of these temperatures the non specific primer 
anneals to the cDNA to prime cDNA amplification. This annealing can 
happen at different sites. In one reaction five fragments of different 
sizes ranging from 1000 bp-170 bp (fig. 32A, section 1.9.1). The 
weaker fragments correspond to the fragments annealed and 
polymerised at the temperatures at the end of the thermocycling 
programme as they are submitted to less polymerising cycles. The 
stronger fragments correspond to those submitted to the highest 
number of polymerising cycles and hence to fragments annealed at 
temperatures close to the beginning of the thermocycling programme.
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The fragments at 1000 and 500 bp are annealed at low temperatures as 
they are only visible with the touch up thermocycling programme (fig. 
32A, section 4.9.1.).
Regions 1 and 2 contain aminoacids residues that have been 
shown to be involved in the interaction with the metal ions (commonly 
Zn2+. Mg2+ or Mn2+) described from the three dimensional structure 
of bovine lens LAP complexed with bestatin. Hence this site is also the 
active site (Burley et al., 1992). Regions 1, 2 and 3 are well conserved 
in all the leucine aminopeptidase proteins available in the Blast 
Network Service except Aeromonus proteolytic a (Guenet et al., 1992) 
leucine aminopeptidase which does not align with these conserved 
regions (data not shown). The aminoacids which interact with bestatin 
are also well conserved and are located in these 3 regions (Burley et 
al., 1992\ Wood et al., 1993). From the computed consensus nucleotide 
sequence corresponding to the most conserved nucleotide sequence, 
more specific primers have been designed. BB10., was designed from 
region 3 using Bovine lens and E. coli leucine aminopeptidase only, 
however inclusion of other nucleotide sequences does not increase the 
specificity of BB10., design in this region. Region 3 is not an ideal 
region for primer designing.
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5.6. Summary and suggestions.
Two methods have been described to obtain highly purified 
aminopeptidase (>100-fold) in two steps. The P. c. chabaudi 
aminopeptidase activity is probably composed of four different leucine 
aminopeptidase with molecular weights ranging from 60-90 kDa. The 
enzyme is a metallo-protease although Zn2+ does not appear to be the 
metal co-factor for enzymatic activity. The enzyme is moderately 
thermophilic and shows simple Michaelis-Menten kinetics with respect 
to L-leucine-AMC. It is inhibited in a competitive manner by bestatin 
and nitro-bestatin. However the bestatin binding site of this enzyme 
appears to differ from the mammalian bestatin binding site. 
Aminopeptidase inhibitor bestatin shows potential anti-malarial activity 
both in vivo and in vitro. Primers Nani and Nan2 were designed from 
the most conserved regions with respect to the nucleotide sequence and 
aminoacid sequence. These primers can be used to screen the cDNA 
library as labelled nucleotide probes or as PCR primers. They are 
specific without wobble sequences.
Drug designing and delivery.
For a drug to be effective it must be effectively delivered primarily to 
the infected erythrocytes and minimally to other parts of the body. Use 
of carrier molecules such as glycoproteins or antibodies with 
recognition sites on the surface of the malarial parasites cell surface 
have shown increased therapeutic effects (Singh et al., 1993). The
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bestatin binding studies revealed possible differences between 
mammalian and malarial aminopeptidases at the active site. Attaching 
bestatin or an effective bestatin analogue to this antibody can be used 
for site specific drug targeting. However the malarial aminopeptidase 
has not yet been localised. Only one description of P. c. chabaudi 
aminopeptidase localisation has been reported so far to my knowledge 
(Slomianny et al., 1983). To confirm this report localisation studies 
could be attempted by using the fluorogenic substrate leucine AMC.
The idea being that when the fluorogenic substrate is added to malarial 
parasites it will bind to the aminopeptidase and the site of binding could 
be visualised by fluorescent microscopy. Monoclonal antibodies against 
the malarial aminopeptidase if they are found to be strictly selective for 
malarial aminopeptidase would be even better candidates to localise the 
aminopeptidase.
The in vivo and in vitro antimalarial studies suggested that the 
polarity of bestatin and nitro bestatin was interfering the anti-malarial 
effects of these aminopeptidase inhibitors. However, activity assays 
have shown that the addition of a polar group N02 on the phenyl ring 
of bestatin to produce nitro-bestatin created a more effective 
aminopeptidase inhibitor and this higher efficiency was observed when 
P. falciparum was cultured in vivo in the presence of nitro-bestatin 
Elimination or modification of any functional polar groups reduces the 
inhibiting effects of some bestatin analogues (Table 3 & 4 section
4.8.2). These polar groups and the bulky phenyl ring appear to be 
essential for aminopeptidase activity inhibition. However polar 
molecules are not the best candidates to cross membrane barriers but 
transport systems for this type of molecules do exist in the membranes 
(glucose transporter for example, (Wingard et al., 1991).
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H3c ,
h3c
Nitro-bestatin
Chloroquine
Bestatin could be rendered less prone to proteolysis by blocking 
the peptide bond hence making bestatin or nitro-bestatin a non- 
hyrolysable peptidomimetic. This may decrease the renal clearance of 
bestatin and therefore the required dose to obtain a therapeutic effect. 
The alkyl chain of leucine could be increased as this would increase 
liposolubility of bestatin. Addition of an extra phenyl would make the 
molecule almost analogous to chloroquine. The resulting molecule 
would resemble chloroquine yet maintain the functional groups of 
bestatin, hence maybe the mechanism by which chloroquine is 
delivered to it's site of action could be appropriate for this molecule.
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This suggested molecule would look like this:
Chloroquine/Bestatin analogue
X should be an electronegative atom like Cl or F.
5.7. Conclusion.
Malarial leucine aminopeptidase activity from P. c. chabaudi is 
probably composed of four monomeric enzymes with a very close 
apparent molecular weight of 63 ± 10 kDa. An N-terminal sequence on 
the four bands revealed by Western blotting needs to be performed in 
order to confirm this suggestion. It is a moderately thermophilic 
enzyme with a near neutral pH optimum of 7.2 and displays optimum 
activity at 50-55°C. This aminopeptidase could be implicated in the 
degradation of haemoglobin derived peptides, into free aminoacids, 
used by the parasite for nutrition and growth. Due to the acidic pH of 
the food vacuole in which haemoglobin degradation is initiated, a 
transport system (Gero & Kirk, 1994) of haemoglobin derived peptides 
from the food vacuole towards a near neutral cellular environment 
would be essential for the aminopeptidase to display optimum activity. 
However it is possible that in physiological conditions this enzyme 
could degrade haemoglobin derived peptidases in the food vacuole, as
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enzymes have been shown to have physiological activity in cellular 
environments with different pHs as those observed in vitro.
The aminopeptidase inhibitor bestatin and it's synthetic analogue 
nitro-bestatin have been shown to have antimalarial effects on P. c. 
chabaudi and P. falciparum chloroquine resistant and sensitive strains. 
In addition the binding kinetics of bestatin to the malarial 
aminopeptidase have been shown to differ from those observed with 
mammalian aminopeptidases. These findings indicate a possible 
difference in the active site of the malarial and mammalian 
aminopeptidase that could be exploited for selective antimalarial drugs 
design.
Bestatin is currently being used as a therapeutic agent for various 
diseases due to it's effects as a biological modifier and an analgesic 
agent. For the first time it is shown in this thesis that aminopeptidase 
inhibitor bestatin or it's analogues are also potential antimalarial 
agents. However a more intensive study on the in vivo antimalarial 
effects of bestatin is necessary.
Primers / nucleotide probes have been designed from a 
conserved region of leucine aminopeptidases in terms of aminoacid and 
nucleotide sequence. These primers can be used for future cloning of 
plasmodial leucine aminopeptidases.
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APPENDIX
Alignment of Leucine aminopeptidases.
Leucine aminopeptidase sequences were retrieved from the Blast 
Network Service and aligned using the SeqEd multiple alignment 
programme. Regions 1, 2, and 3 are highlighted in the computed 
consensus and contain aminoacids involved in bestatin and metal ion 
interactions. (Burley et al., 1992).
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